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Obesity is becoming one of the most prevalent public health problems around 
the world. It is associated with various metabolic disorders, such as insulin 
resistance, type 2 diabetes, non-alcoholic fatty liver disease and different vascular 
diseases. However, the mechanisms that lead to insulin resistance in type 2 
diabetes and other metabolic syndromes have not been well understood. In this 
study, we discovered two proteins, interferon regulatory factor 3 (IRF3) and 
MAPK phosphatase 5 (MKP5), which play important roles in the development of 
obesity-related metabolic diseases. 
IRF3, a master regulator of type I interferon which is essential for immune 
response against virus infection, has been implicated in adipogenesis and high fat 
diet induced hepatic steatosis. However, the role of IRF3 in adipocyte and adipose 
tissue is not known. Here, we found that IRF3 is a negative regulator of 
adipogenesis and adipose tissue inflammation thereby acts to inhibit the 
development of obesity and obesity-associated complications. During 
adipogenesis, IRF3 deficient pre-adipocytes showed increased adipogenesis 
associated with increased expression of PPARγ and PPARγ-regulated 
adipogenesis program.  Mice deficient in IRF3 developed obesity and type 2 
diabetes exhibite insulin resistance, glucose intolerance, hyperinsulinemia, 
hyperglycemia as well as hepatic steatosis spontaneously with age. The 
development of these metabolic disorders in IRF3 deficient mice was associated 
with increased adipose tissue inflammation characterized by increased 




adipogenesis and adipose tissue inflammation and could be a target for 
therapeutic interventions for obesity and obesity-associated metabolic disorders. 
MKP5 is a negative regulator of MAPKs and plays an important role in 
inflammatory responses. Here we found that MKP5 has protective role in the 
development of hepatic steatosis. Mice deficient in MKP5 had increased 
accumulation of triglycerides in the liver and developed hepatic steatosis under 
normal chow. Upon high fat diet feeding, mice deficient in MKP5 developed 
more severe hepatic steatosis compared with wildtype (WT) mice, which was 
associated with increased p38 MAPK activity in the liver. Interestingly, 
deficiency of MKP5 led to dramatically increased expression of lipid-droplet-
associated protein genes Cidea and Fsp27 in the liver. Furthermore, 
overexpression of MKP5 inhibited Cidea and Fsp27 promoter activity in 
hepatocytes, which was dependent on the phosphatase activity of MKP5. We 
further found that treatment with p38 inhibitor attenuated the development of 
hepatic steatosis in both WT and MKP5 KO mice by reducing expression of 
Cidea and Fsp27 in the liver. Therefore, MKP5 played an important protective 
role in the development of hepatic steatosis at least in part through regulation of 
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Obesity has become an increasingly prevalent public health problem 
worldwide, which developed as a result of complex interaction between 
developmental, behavioral, genetic and environmental factors (Valdar et al., 
2006). In human, obesity results from increased food intake, particularly a diet 
high in calories and fat content, combined with decreased energy expenditure 
associated with modern lifestyle (Bjorntorp, 1997). Obesity increases the risks of 
other metabolic disorders including insulin resistance, type 2 diabetes and non-
alcoholic fatty liver diseases (NAFLD) (Haslam and James, 2005). Given that the 
epidemic of obesity and obesity-associated metabolic disorders is a worldwide 
health burden, a better understanding of the etiology of obesity and obesity-
associated metabolic disorder is required. 
In the first chapter, an overview of obesity and obesity- associated metabolic 
disorders including insulin resistance and fatty liver diseases as well as the 
pathogenesis of these metabolic syndromes is presented. 
1.1 Obesity 
Obesity is a leading preventable cause of death worldwide, with increasing 
prevalence in adults and children (Barness et al., 2007). It is defined as a state of 
increased body weight, particularly adipose tissue, of sufficient magnitude to 
produce adverse effect on health and even lead to reduced life expectancy 
(Spiegelman and Flier, 2001). People are considered obese when their body mass 
index (BMI, a measurement obtained by dividing a person's weight in kilograms 






development of obesity is thought to be influenced by multiple factors including 
life style, genetics, behaviour and environmental factors. In obesity, these factors 
influence food intake and energy expenditure leading to a positive energy balance 
that accounts for the expansion of fat mass by increasing the size and number of 
adipocytes (Spiegelman and Flier, 2001). Energy intake, energy expenditure and 
energy storage determine an individual’s energy balance status. People take in 
energy in the form of carbohydrate, fat and protein and spend energy through 
resting metabolic rate (RMR), thermic effect of food and physical activity. Body 
weight will change when energy intake is not equal to energy expenditure over a 
given period of time. When energy intake exceeds energy expenditure, a state of 
positive energy balance occurs. The consequence of positive energy balance is an 
increase in body mass, particularly the amount of body fat (Hill and Commerford, 
1996). Conversely, when energy expenditure exceeds energy intake, a state of 
negative energy balance ensues. The consequence is a loss of body mass (Hill et 
al., 2012). Although obesity can be caused by genetic factors, endocrine disorders, 
medications or psychiatric illness, most cases of obesity are caused by a 
combination of excessive food energy intake, lack of physical activity and genetic 
susceptibility. 
1.2 Adipose tissue and adipocytes 
1.2.1 Adipose tissue 
Adipose tissue, also known as fatty tissue, is a connective tissue 




(SVF). SVF is a heterogenic cell population including a variety of immune cells 
including adipose tissue macrophages (ATMs), T cells, fibroblasts and vascular 
endothelial cells (Weisberg et al., 2003). The main function of adipose tissue is to 
synthesize and store large globules of fat within a structural network of fibres. 
They are distributed not only under the skin but also in deposits between the 
muscles, in the intestines and their membrane folds and around the heart (Tran 
and Kahn, 2010). In mammals, there are two kinds of adipose tissues: white 
adipose tissue (WAT) and brown adipose tissue (BAT). These two types of 
adipose tissues display different features and functions, which are discussed in the 
following sections. 
1.2.1.1 White adipose tissue 
As the most common and principle type of adipose tissue in mammals, WAT 
has long been recognized as the main site of storage of excess energy (Rosen and 
Spiegelman, 2006). When muscles and other tissues need energy, certain type 
of hormones bind to adipocytes and trigger the release of energy from energy-
rich fatty acids and glycerol. WAT is scattered throughout the body and mainly 
occupies positions in skin as well as around and within other various organs 
(Figure 1.1A) (Tran and Kahn, 2010). It can be also found in significant amount 
in the omentum and mesentery (which is known as visceral WAT) and around the 
kidneys. WAT forms a distinct tissue layer beneath the dermis of the skin which 
is known as subcutaneous WAT. Visceral and subcutaneous WATs are the 




contains mostly unilocular adipocytes whereas subcutaneous WAT is more 
heterogeneous, containing both uni- and multi-locular adipocytes and interstitial 
tissue (Figure 1.1B) (Berry et al., 2013). 
Although the main function of WATs is to control energy balance by storing 
and mobilizing triglyceride, they are also endocrine and paracine organs (Rosen 
and Spiegelman, 2006; Schaffler et al, 2006). The discovery of leptin production 
by adipocytes marked the first indication that WAT functions as an endocrine 
organ. It is now clear that WAT secretes a large number of peptide hormones and 
adipokines as well as non-peptide biologically active molecules such as activated 
lipids (Kershaw and Flier, 2004). These molecules affect energy metabolism of 
not only WAT, but also other tissues such as the liver and skeletal muscle, and 
behaviours related to feeding through effects on neuroendocrine pathways 
(Bartness and Song, 2007).  
1.2.1.2 Brown adipose tissue 
Brown adipose tissue is a specialized form of adipose tissue with particular 
function in regulating body temperature. As a thermogenic tissue, it is a site of 
energy dissipation in contrast to the energy storing of WAT.  Morphologically, 
BAT is different from WAT with uniformity of multilocular lipid droplets in the 
cells. Besides that, the size of brown adipocytes is much smaller than that of white 
adipocytes (Figure 1.1B) (Berry et al., 2013).  Heat production in brown fat is 
very important for maintaining body temperature and the survival of mammals in 




brown adipocytes and is critical to uncoupling of brown fat mitochondrial 
respiratory chain to mediate heat production in BAT (Klaus et al., 1991). Recently, 
metabolism regulation by BAT has received increased attention due to the 
discovery of the role of BAT thermogenesis in excess energy dissipation that 
prevented obesity (Vila-Bedmar and Fernandez-Veledo, 2011). 
 
Figure 1.1 Distribution and heterogeneity of adipose tissue. (A) Distribution of 
adipose tissue in mice (Tran and Kahn, 2010). (B) Pictures of various adipose 
tissues are shown in the top panel. H&E staining of the respective adipose tissue 
sections is shown in the lower panel. (a) subcutaneous(SQ) fat depots, (b) 




1.2.2 Adipocytes and adipogenesis 
1.2.2.1 Adipocytes 
Adipocytes, also known as lipocytes or fat cells, primarily compose of 
adipose tissue to store fat.  Adipocytes are characterized into white adipocytes and 
brown adipocytes which have distinct cell morphology and can be readily 
recognized under a light or electron microscope (Cinti, 2000; Cinti, 2001a; Cinti, 
2001b). White adipocytes are generally spherical cells with an average diameter 
of less than 10μm in young mice. However, this size can increase to as much as 
100μm, particularly in the epididymal (visceral) fat depots (Cinti, 2005). Each 
white adipocytes contain single, large lipid droplets that takes up the majority of 
the cell volume, leaving the cytoplasm and nucleus restricted at the cell periphery. 
The organelles in the cytoplasm, such as the mitochondria, golgi and smooth and 
rough endoplasmic reticulum, are poorly developed. On the other hand, brown 
adipocytes are smaller than white adipocytes and their cytoplasm contains several 
lipid droplets. Thus these cells are also called multilocular adipocytes. In addition 
to lipid droplets, the cytoplasm of brown adipocytes have a roundish nucleus and 
numerous, large, generally spherical mitochondria with laminar cristae. These 
mitochondria contain a unique protein, UCP1, that supports the thermogenic 
function of brown adipocytes (Klaus et al., 1991). The different morphology of 
white and brown adipocytes implies that they have distinct functions in 
metabolism. For instance, white adipocytes store energy in the form of lipids that 
can be released to other metabolic tissues between meals. (Kershaw and Flier, 




temperature in response to cold by burning lipids to produce heat in BAT 
(Giordano et al., 2014).  
1.2.2.2 Adipogenesis  
An increase in adipocyte number (adipocyte hyperplasia) and/or size of 
individual fat cells (adipocyte hypertrophy) results in adipose tissue expansion in 
obesity (Hirsch and Batchelor, 1976). In general, the increase in adipocyte 
number is achieved by adipogenesis. Adipogenesis is defined as the 
differentiation of fibroblast-like preadipocytes into mature lipid laden, insulin-
responsive adipocytes (Lefterova and Lazar, 2009). It is a two-step developmental 
process. During this process, an undifferentiated mesenchymal cell first 
differentiates into a preadipocyte and then undergoes a secondary differentiation 
step to become a lipid-laden adipocyte. Each step of adipogenesis requires to be 
properly regulated in order to achieve functional adipocytes. In the past decades, 
adipogenesis was one of the most intensively studied developmental processes 
due the availability of in vitro pre-adipose cell models such as 3T3-L1 pre-
adiocytes and OB17 cells that faithfully recapitulated most of the critical aspects 
of fat cell formation in vivo (Brandes et al., 1987; Grimaldi et al., 1982). More 
recently, studies of adipogenesis have proceeded with the hope that manipulation 
of this process in humans might lead to reduction in the burden of obesity and 




1.2.2.3 The regulation of adipogenesis 
Adipocyte differentiation is a complex process that involves a temporally 
regulated set of gene expression events. An understanding of the underlying 
transcriptional networks of adipogenesis is of great importance. In the past 
decades, studies have elucidated the critical roles of nuclear receptors, the 
peroxisome proliferator-activated receptor γ (PPARγ) and the CCAAT/enhancer-
binding (C/EBP) proteins, in the regulation of adipogenesis. Recently, 
accumulating evidence has implicated many other positive and negative 
regulators of adipocyte development. In the following sections, we will provide 
an overview of some crucial transcription factors and regulators in adipogenesis. 
PPARγ: a master regulator of adipogenesis 
PPARγ is a member of the PPAR nuclear hormone receptor superfamily and 
is the target of the anti-diabetic drugs thiazolidinedione (TZD) (Larsen et al., 
2003). It exists as two isoforms, PPARγ1 and PPARγ2. PPARγ1 is expressed in 
many cells and tissues such as adipocytes, macrophages and cells of the 
vasculature and the colon. Additionally, PPARγ2 is exclusively expressed in the 
adipose tissue.  
The role of PPARγ in adipogenesis in vitro was discovered independently by 
two research groups. Mitchell and his colleagues found that PPAR ligands could 
substitute for the adipogenic hormones during the differentiation of preadiocytes 
to adipocytes (Chawla and Lazar, 1994). Subsequently, they demonstrated that 




1994). Spiegelman and his colleagues cloned PPARγ2 as a component of adipose 
regulatory factor 6 (ARF6), which activates the enhancer of adipocyte P2 (aP2) 
gene through ARF6 binding sites (Tontonoz et al., 1994).   
Gene-targeting studies on PPARγ have revealed the role of PPARγ in 
adipogenesis in vivo. Although PPARγ null mice are lethal relatively early in 
gestation (E10–10.5) and secondary to a defect in placental development (Barak 
et al., 1999; Kubota et al., 1999), the regulatory role of PPARγ in the 
development of adipose tissues was still ascertained by three different laboratories 
using various approaches. The first approach was to create chimeric embryos 
using a combination of wild-type tetraploid cells that allowed rescue of the 
placental defect and PPAR null cells that were the sole contributor to the embryo 
property. Using this approach, one homozygous mutant mouse was developed to 
term, athough it died shortly after birth (Barak et al., 1999). In this study, brown 
fat depots were significantly reduced in PPARγ null neonate, indicating the 
important role of PPARγ in regulation of brown adipose tissue development. 
Another approach was to create chimeric mice derived from both wild-type ES 
cells and cells with a homozygous deletion of PPARγ. This strategy allowed to 
examine the contribution of PPARγ null cells to adult tissues and demonstrated 
the requirement of PPARγ for adipogenesis in vivo. It was also shown that PPARγ 
was required for the in vitro differentiation of adipose cells from ES cells (Rosen 
et al., 1999). Finally, the role for PPARγ in adipogenesis in humans is suggested 
by the results of clinical trials of PPARγ agonists in liposarcoma, a malignant 




the PPARγ agonists (Tontonoz et al., 1997).  Collectively, these studies 
demonstrated that PPARγ plays important roles in the regulation of adipogenesis 
both in vivo and in vitro. Mechanistically, PPARγ binds to DNA as a heterodimer 
with retinoid X receptor to regulate the expression of its downstream target genes 
which contain a PPARγ-response element in their promoter regions during the 
differentiation of adipocytes from pre-adipocytes (Desvergne and Wahli, 1999). 
CCAAT/Enhancer-Binding Protein (C/EBPs) 
Another important regulator in adipogenesis is the C/EBPs. C/EBPs belong to 
the basic leucine zipper (bZIP) family of transcription factors. This family has six 
members and these proteins contain the carboxy terminal with a basic DNA-
binding region and a leucine zipper which is responsible for their dimerization 
(Maxwell et al., 1994). Several C/EBP family members, including C/EBPα, 
C/EBPβ, C/EBPγ and C/EBPδ are expressed in adipocytes (Darlington et al., 
1998) .  
In vivo and in vitro experiments have shown that C/EBPα, C/EBPβ and 
C/EBPδ promote adipocyte differentiation. During adipocyte differentiation, the 
expression of these three C/EBPs follows a distinct temporal pattern. C/EBPβ and 
C/EBPδ are expressed early while C/EBPα is expressed at a later phase in 
response to hormonal stimulation during adipogenesis (Rosen and MacDougald, 
2006). The early expressed C/EBPβ and C/EBPδ work in concert to trans-activate 
C/EBP (Cao et al., 1991). The roles of C/EBPβ and C/EBPδ have been 




C/EBPδ impaired WAT growth and adipogensis of MEF ex vivo. Furthermore, 
mice deficient in both C/EBPβ and C/EBPδ have a further decline in adipose-
tissue mass (Tanaka et al., 1997). Surprisingly, the double-knockout mice do 
express normal levels of PPARγ and C/EBPα, indicating that there might be 
compensatory mechanisms for activation of adipocyte gene expression in vivo 
(Tanaka et al., 1997). Although C/EBPα null mice were found to die due to 
hypoglycemia within 8 h of birth, a rescue method by injecting a small amount of 
glucose made it possible to study the function of C/EBPα in adipogenesis. These 
C/EBPα null mice did not have any subcutaneous fat and they displayed much 
smaller brown fat compared with their WT controls (Wang et al., 1995). The 
above evidence indicated the essential roles of C/EBPα in the regulation of 
adipose tissue development. 
Other adipogenic factors 
 
In additional to these central players, PPARγ and C/EBPs, several other 
transcription factors including several KLFs, STAT5 and SREBP-1 have been 
shown to promote adipogenesis, whereas GATA2/3, KLF2, Wnt families and 
TCF/LEF are known to be inhibitors of adipogenesis (Figure 1.2) (Park et al., 
2008; White and Stephens, 2010).   
Krüppel-like family of transcription factors (KLFs) are zinc finger DNA-
binding proteins and have been implicated in regulating development, cellular 
differentiation and proliferation (McConnell and Yang, 2010).These proteins can 




while others act as repressors of transcription. Among them, KLF4, KLF5, KLF6 
and KLF15 have been shown to be positive effectors of adipogenesis. For 
instance, transcription of KLF5 is activated by C/EBPβ and C/EBPδ and, in 
concert with these C/EBPs, contributes to the induction of PPARγ (Oishi et al., 
2005). In addition, KLF5 heterozygous mice have a significant deficiency in 
adipose tissue formation. MEFs from these heterozygous mice are compromised 
in their ability to differentiate into adipocytes (Oishi et al., 2005). 
Signal Transducer and Activator of Transcription (STATs) are primarily 
activated by cytokines and hormones. Upon activation, STATs translocate into 
nucleus to modulate gene transcription (Schindler and Darnell 1995, Darnell 
1997). So far, STAT1, STAT3, STAT5A, STAT5B and STAT6 are found to be 
expressed in adipocytes. During 3T3-L1 adipocyte differentiation, STAT1, 
STAT5A and STAT5B are substantially induced (Stephens et al., 1996), 
indicating important regulatory role of STATs in adipocyte differentiation. 
Ectopic expression studies and transgenic knockout experiments have confirmed 
the physiological relevance of STAT5 in adipogenesis. Ectopic expression of 
STAT5A in 3T3-L1 and nonadipogenic fibroblasts induces preadipocyte 
differentiation, which induces the activation of PPARγ and the accumulation of 
multiple fat droplets (Nanbu-Wakao et al., 2002). Interestingly, STAT5B was 
unable to display similar proadipogenic properties in these nonprecursor cells 
(Floyd and Stephens, 2003). 
Sterol response element-binding protein-1 (SREBP-1) is a helix-loop-helix 




which originate from the same gene through utilization of different promoters 
(Shimomura et al., 1997). SREBP1c is predominantly expressed in WAT and 
regulates lipogenic gene expression, whereas SREBP1a is the more potent 
transcription factor because of a longer N-terminal DNA-binding domain. In vitro 
studies demonstrated the regulatory roles of SREBP1 in adipogenesis. Ectopic 
expression of SREBP-1 in NIH-3T3 fibroblasts promoted adipocyte 
differentiation that was accompanied by increased expression of adipocyte-
specific genes and lipid accumulation. Conversely, overexpression of a dominant-
negative SREBP-1 that contained a point mutation within the DNA-binding 
domain led to profound inhibition of adipocyte differentiation and repression of 
adipocyte marker genes (Kim and Spiegelman, 1996).  
Fibroblast growth factors (FGFs) consist of 22 family members which 
regulate different physiological, developmental and proliferative events. Recent 
studies have revealed positive roles of FGFs in adipogenesis. FGF2 (also called 
basic FGF) can induce the development of adipose tissues when implanted in a 
biological matrix in mice (Kawaguchi et al., 1998).  FGF10 is highly expressed in 
the stromal vascular cells of WAT and is also induced early in the differentiation 
of 3T3-L1 into adipocytes (Sakaue et al., 2002). In addition, deficiency of FGF10 
in MEFs lowered the potential of adipogenesis. Furthermore, mice deficient in 
FGF10 were resistant to the development of obesity with reduced fat pad mass 





Figure 1.2 Transcription factors that are positive or negative regulators of 
adipocyte development (Sarjeant and Stephens, 2012). 
1.2.3 Models for adipocyte differentiation  
A variety of cellular model systems have been developed to study the 
molecular pathways of adipogenesis and adipocyte function in vitro. These 
models can be divided into three cell subtypes: (1) the most commonly used 
model whereby fibroblast-like preadipocytes are committed to differentiate into 
adipocytes, (2) pluripotent fibroblasts that have the ability to differentiate into 
various cell types, (3) primary preadipocyte that can specifically differentiate into 
adipocytes.  
The first class represents the cells that are the most frequently used in 
adipogenesis. 3T3-F442A and 3T3-L1 are the two most extensively characterized 
and used preadipocyte cell lines for study of adipocyte differentiation due to the 




morphologically (Novikoff et al., 1980) and biochemically (MacDougald and 
Lane 1995) similar to adipocytes in vivo. Both of these cell lines were derived 
from disaggregated 17- to 19-day-old Swiss 3T3 mouse embryos (Green and 
Meuth 1974; Green and Kehinde 1976). However, unlike 3T3-L1 cells, 3T3-
F442A preadipocytes do not require glucocorticoid-supplemented differentiation 
cocktail to induce adipogenesis (Rubin et al., 1978; Spiegelman and Ginty 1983; 
Moustaid et al., 1990).  
Besides preadipocyte cell lines, isolated mouse embryonic stem cells and 
mouse embryonic fibroblasts can also be differentiated into adipocytes using 
induction medium. The TA1 cell line was established by treating CH310T1/2 
mouse embryo fibroblast cells with the demethylating agent 5-azacytidine. These 
cells can be differentiated into cells showing morphological and biochemical 
features of muscle, bone and adipose tissue. Unlike 3T3-L1 cells, pluripotent 
C3H10T1/2 stem cells do not differentiate into adipocytes when exposed to 
adipose differentiation inducers (Konieczny and Emerson, 1984). Instead, the 
treatment of proliferating C3H10T1/2 cells with BMP4 can induce commitment 
of these cells to adipocyte lineage cells, which can later be differentiated into 
adipocytes in the presence of adipocyte differentiation inducers (Tang et al., 
2004). 
As the stage of differentiation and the lineage of preadipocyte cell lines have 
not been well understood and established, primary cultures have been particularly 
useful for validating results obtained from preadipose cell lines (Gregoire et al., 




number of species including humans and rodents. There are several advantages to 
use primary culture for the study of adipogenesis. Firstly, primary cells are diploid 
and reflect the in vivo context better than aneuploid cell lines. Secondly, they can 
be derived from adipose tissue obtained from various species and different 
adipose tissues. The latter is of particular importance, as molecular and 
biochemical differences in fat pads have been observed. Such differences may 
have major physiological consequences, since excessive fat accumulation is more 
importantly associated with increased morbidity in humans than subcutaneous fat 
accumulation (Kissebah and Krakower, 1994). 
1.3 Insulin signaling pathways and insulin resistance 
Obesity induces an insulin resistant state in adipose tissue, liver and skeletal 
muscle and acts as a major risk factor for diseases including type 2 diabetes 
mellitus and cardiovascular diseases (Bastard et al., 2006). Insulin controls critical 
energy functions such as glucose and lipid metabolism in adipose tissue, liver and 
skeletal muscle. A failure to respond to insulin by the metabolic tissues may lead 
to the development of insulin resistance. Thus, it is necessary and essential to 
understand the insulin signalling pathways and the underlying mechanism that 
lead to the development of insulin resistance. 
1.3.1 Insulin signaling pathways 
Insulin is a peptide hormone secreted by β cells of the pancreatic islets of 
Langerhans. This hormone maintains normal blood glucose levels by facilitating 




promoting cell division and growth through its mitogenic effects (Wilcox, 2005). 
After a meal, insulin promotes uptake and storage of glucose as glycogen in 
skeletal muscle and the liver, at the same time, inhibits hepatic glucose production 
via decrements in glycogenolysis and gluconeogenesis. Insulin also promotes 
triglyceride storage by suppressing fatty acid oxidation, increasing lipid synthesis 
in the liver and adipose tissues and in fat cells through an anti-lipolytic effect. 
During periods of fasting, a fall in circulating insulin combined with increased 
secretion of counter-regulatory hormones leads to a breakdown of stored 
triglycerides and increase the availability of metabolic substrates for cellular 
energy. Thus, insulin plays an essential role in maintaining blood glucose level 
within a narrowly defined range despite large fluctuation in food intake.  
The insulin signaling pathways are important biochemical pathways 
beginning at the cellular level to affect metabolic homeostasis (Figure 1.3) (Saltiel 
and Kahn, 2001). In mammalian cells, insulin binds to its receptor to activate the 
insulin receptor (IR) tyrosine kinase. Activated IR tyrosine kinase in turn 
phosphorylates and recruits different substrate adaptors such as the IRS family of 
proteins. Phosphorylated IRS proteins bind specific Src-homology-2 domain 
(SH2) proteins such as phosphatidylinositol 3-kinase (PI3K) and phosphotyrosine 
phosphatase SHPTP2 (or Syp) as well as other intracellular signalling proteins, 
e.g. the adaptor protein Grb2 which connects with the RAS (rat sarcoma protein) 
pathway (Wilcox, 2005). PI3K has a major role in insulin action, mainly via the 
activation of Akt/PKB and the PKC cascades. Activated Akt/PKB in turn 




synthase. Activation of Akt/PKB also results in the translocation of GLUT-4 
vesicles from their intracellular pool to the plasma membrane, allowing glucose 
uptake. In addition, insulin signaling inhibits the production and release of 
glucose in the liver by blocking gluconeogenesis and glycogenolysis via 
controlling metabolic enzymes in these processes (Burks and White, 2001). 
Besides the functions above, insulin also has growth and mitogenic effects which 
are mostly mediated by the Akt cascade and the activation of the Ras/ MAPK 
pathway (Saltiel and Kahn, 2001). Therefore, multiple signaling pathways are 
activated in response to insulin and act in a concerted fashion to coordinate the 
regulation of vesicle trafficking, protein synthesis, enzyme activation and 
inactivation and gene expression, resulting in the regulation of glucose, lipid and 
protein metabolism. 
 
Figure 1.3 Insulin signaling pathways. Multiple signaling pathways respond to 
insulin and act in a concerted fashion to regulate glucose, lipid and protein 




1.3.2 Insulin Resistance 
Insulin resistance is a physiological condition in which cells fail to respond to 
insulin. Under the insulin resistant condition, the body produces insulin, but the 
cells in the body are unable to use it effectively, leading to increased blood 
glucose level known as hyperglycemia. β cells in the pancreas subsequently 
increase their production of insulin to compensate the ineffective response to 
insulin, which lead to increased plasma insulin concentration known as 
hyperinsulinemia. Previous studies have demonstrated that insulin resistance in 
muscle and fat cells reduces glucose uptake, whereas insulin resistance in liver 
cells results in a reduction in both glycogen synthesis and storage as well as a 
failure to suppress glucose production and release into the blood (Wilcox, 2005). 
In addition, insulin resistance also affects other functions of insulin in cells. For 
instance, insulin resistance in fat cells reduces the normal effects of insulin on 
lipids and results in reduced uptake of circulating lipids and increased hydrolysis 
of stored triglycerides. Then increased mobilization of stored lipids in fat cells 
elevates free fatty acids in the blood plasma, which contributes to elevated blood 
glucose levels (Wilcox, 2005). The high levels of blood glucose and insulin due to 
insulin resistance increase the risks of other metabolic disorders such as type 2 
diabetes, non-alcoholic fatty liver diseases and vascular diseases (Wilcox, 2005). 
 Several factors contribute to the development of insulin resistance. Obesity 
and a diet rich in fats and refined carbohydrates are high risk factors to be 
associated with the development of insulin resistance. Besides that, physical 




to the use of more glucose by the muscle during exercise in comparison with other 
metabolic tissues. Besides the risk factor associated with lifestyle which can be 
modified, there are other genetic or biochemical factors that contribute to the 
development of insulin resistance, which are not easily modifiable. For instance, 
genetic defects in the insulin receptor cause the most severe forms of insulin 
resistance, exemplified by the Rabson Mendenhall Syndrome, leprechaunism and 
the type A syndrome of insulin resistance (Taylor and Arioglu, 1998).  
1.3.3 Assessment of insulin resistance 
Since insulin is an important hormone and regulates different cell processes, 
assessment of insulin sensitivity/resistance in humans and animal models is of 
great importance for epidemiological studies, clinical and basic science 
investigations. So far, several direct and indirect methods have been developed to 
diagnose insulin resistance in vivo. Some approaches rely on steady-state analysis 
of glucose and insulin, whereas others rely on dynamic testing (Muniyappa et al., 
2008). 
In human, the fasting condition represents a basal steady state where glucose 
is homeostatically maintained in the normal range such that insulin levels are not 
significantly changing. Therefore, the simplest and fastest way to determine 
insulin resistance is to measure the fasting glucose levels and fasting insulin levels 
in the blood. If the fasting insulin level is higher than 60pmol/L, it is considered 




Another indirect way to measure insulin sensitivity in mouse is to perform a 
glucose tolerance test (GTT) and an insulin tolerance test (ITT). The GTT 
measures the clearance of an intraperitoneally injected glucose load from the body. 
It is used to detect disturbances in glucose metabolism that can be linked to 
conditions such as diabetes or metabolic syndrome (Toffolo and Cobelli, 2003; 
Vicini et al., 1997). The ITT measures glucose levels subsequent to a standardized 
insulin load. This method provides an estimate of insulin sensitivity of the 
animals (Muniyappa et al., 2008).  
The hyperinsulinemic englycemic glucose clamp technique is one of the 
direct methods to measure insulin sensitivity. It is originally developed by 
DeFronzo et al. and now is widely accepted as the golden standard for 
determining metabolic insulin sensitivity in both human and mouse (DeFronzo et 
al., 1979). Intravenous administration of insulin at a constant rate raises and 
maintains systemic insulin levels (“hyperinsulinemic”) during euglycemic clamps. 
Glucose is intravenously infused at variable rates to maintain “euglycemia”, and 
the steady-state rate of glucose infusion directly correlates with insulin sensitivity. 
Incorporation of radioactive-labelled glucose during euglycemic clamps further 
measures glucose metabolism in individual organs (DeFronzo et al., 1979). 
Despite the wealth of information provided by the euglycemic clamp, the 
sophisticated and technical nature of this procedure has limitations on its use and 
implementation. 
Besides the approaches described above, there are other methods to 




directly measures metabolic insulin sensitivity/resistance in patients (Harano et al., 
1978). On the other hand, the homeostasis model assessment index of insulin 
resistance (HOMA-IR) uses simple equation to compute a surrogate index of 
insulin resistance based on steady state basal glucose and insulin concentrations in 
human and mouse (Matthews et al., 1985).  
1.4 Obesity-associated adipose tissue inflammation 
Obesity is frequently associated with a state of chronic, low-grade 
inflammation in liver and adipose tissues. It is often accompanied with increased 
inflammatory cell infiltration as well as local secretion of cytokines and 
chemokines that attenuate insulin action (Weisberg et al., 2003; Xu et al., 2003a). 
In the following sections, an overview of obesity-associated adipose tissue 
inflammation and adipose tissue macrophage infiltration and activation, as well as 
the contribution of inflammation to obesity-associated metabolic diseases will be 
presented.  
1.4.1Adipose tissue inflammation: the link between obesity and insulin 
resistance 
Obesity induces a chronic, low-grade inflammation, which is implicated in 
many clinical complications including insulin resistance, diabetes, atherosclerosis 
and non-alcoholic fatty liver disease (Lumeng and Saltiel, 2011). The first 
realization of the relationship between inflammation and insulin resistance can be 
dated back to the findings that treatment of inflammatory condition, such as 




salicylate and aspirin, were able to lower blood glucose concentration and 
improve insulin sensitivity (Williamson, 1901).  Although some additional 
epidemiological studies have subsequently ascertained these early findings (Grace 
and Goldrick, 1968), these discoveries still did not influence the thoughts about 
the pathogenesis of insulin resistance and other metabolic complications for a 
period of time. In the last decade, growing evidence showed a relationship 
between inflammation and insulin resistance. For instance, the proinflammatory 
cytokine TNFα has been shown to mediate obesity-induced insulin resistance in 
many rodent obesity models (Hotamisligil et al., 1993). Mice deficient in TNFα or 
TNF receptor are resistant to develop obesity- associated insulin resistance (Uysal 
et al., 1998; Uysal et al., 1997). Mice deficient in JNK1, another key mediator of 
inflammatory responses, have improved systemic insulin sensitivity (Hirosumi et 
al., 2002). In addition, a study of high fat diet-induced obese mouse model 
showed that an increase in body fat mass was associated with an increased 
infiltration of macrophages, T cells and other leukocytes as well as a change in 
the phenotypes adipose tissue macrophages (ATMs) from M2 to M1 which is 
inflammatory (Lumeng et al., 2007; Xu et al., 2003a). All these evidence 
supported inflammation as the link between obesity and insulin resistance in 
WAT. 
Although inflammation is now considered as the link between obesity and 
insulin resistance and other metabolic disorders, the cause and the molecular 
participants in this process underlying the pathogenesis of these metabolic 




adipocyte-generated cytokines recruit monocytes and T cells to the obese adipose 
tissue and promote the differentiation of monocytes to inflammatory macrophage 
to initiate systemic inflammation (Baker et al., 2011). In addition, metabolic stress 
resulting from overnutrition is also known to activate inflammatory pathways. For 
instance,  the elevation of FFA in adipose tissue and blood and an excess of 
metabolic building blocks in the endoplasmic reticulum (ER) can initiate 
inflammatory pathways in vascular endothelial cells, adipocytes and myeloid-
derived cells (Kim et al., 2005). On the other hand, the increased death of 
adipocytes in obese adipose tissue could recruit macrophages to clear the dead 
cells. It has been observed that the infiltrated ATMs organize crown-like 
structures around large dead or dying adipocytes and cytokines such as TNFα and 
IL-6 were released to further activate the inflammatory program in neighboring 
adipocytes, exacerbating inflammation and insulin resistance (Medina-Gomez et 
al., 2007).  
1.4.2 Adipose tissue macrophage (ATM) 
Adipose tissue is considered as an important initiator of inflammatory 
response to obesity. This heterogeneous tissue comprises a variety of cell types 
including mature adipocytes, pre-adipocytes, endothelial cells, fibroblasts, 
macrophages and other immune cells (Geloen et al., 1989). Recent findings 
demonstrated that infiltration of inflammatory cells into adipose tissue in obesity 
could be integral to the inflammatory changes (Weisberg et al., 2003; Xu et al., 




recognized as important non-adipocyte cells that contribute to the production of 
pro-inflammatory cytokines and chemokines (Weisberg et al., 2003). Of note, it 
has been reported that adipocytes can also secrete adipokines such as resistin and 
adiponectin in insulin-resistant condition to attract further infiltration of 
inflammatory cells (de Luca and Olefsky, 2008).  
1.4.2.1 Macrophages: M1/M2 phenotype 
Macrophages are remarkably plastic and are capable of adapting to different 
tissue microenvironments. Like Th1/Th2 for T helper cells, a concept of M1/M2 
polarization has been developed for macrophages. According to this concept, 
macrophages can be classified into pro-inflammatory M1 (“classically activated”) 
or anti-inflammatory M2 (“alternatively activated”) phenotype (Mantovani et al., 
2002). Macrophages acquire M1 or M2 phenotypes depending on the stimuli such 
as cytokines and exert unique functional properties (Biswas and Mantovani, 2010). 
For instance, upon stimulation with interferon gamma (IFN-γ) alone or in 
combination with TLR ligands such as lipopolysaccharide (LPS) in vitro, 
macrophages acquire M1 phenotype (Biswas and Mantovani, 2010). In contrast, 
exposure to IL-4 or IL-13 or combination of IL-4 and IL-13 will lead to 
macrophage M2 phenotype (Gordon, 2003). “Classically activated” M1 
macrophages secrete high levels of pro-inflammatory cytokines including TNFα, 
IL-6, IL-1β and generate reactive oxygen and nitrogen species such as nitric oxide 
via activation of inducible nitric oxide synthase (iNOS) (Biswas and Mantovani, 




iNOS activity and thereby inhibits nitric oxide production. M2 macrophages also 
secrete anti-inflammatory cytokines (e.g. IL-10, TGF-β, IL-4) which are essential 
to resolve the inflammatory response (Gordon, 2003).  
1.4.2.2 Obesity-induced ATM phenotypic change 
Adipose tissues contain both M1 and M2 macrophages (Marinez et al., 2006). 
These M1 and M2 macrophage can be distinguished by assessing the expression 
of respective markers. M1 macrophages are characterized by expression of F4/80, 
CD11c and iNOS, whereas M2 macrophages are characterized by expression of 
F4/80, Arg and CD301 (Martinez et al., 2006). The different phenotypes and 
functions of these two types of macrophages reflect their local metabolic and 
immune microenvironment (Figure 1.4). Under lean condition, adipocytes secret 
adipokines such as IL-13, thus promote the alternative activation of macrophages 
(M2 macrophages). M2 macrophages, in turn secret anti-inflammatory cytokines 
such as IL-10 and some insulin- sensitizing factors to maintain adipose tissue 
homeostasis. Over-nutrition leads to obesity and changes both glucose and lipid 
metabolism in adipocytes. This results in increased lipolysis and the release of 
FFA and other pro-inflammatory factors, which lead to recruitment of 
macrophages into adipose tissue and macrophage M1 activation, thereby to 
augment adipose tissue inflammation and promote insulin-resistance (Kosteli et 
al., 2010).  For instance, consumption of HFD shifted cytokine expression by 
murine ATMs from M2- to M1-like patterns with decreasing expression of IL-10 




2007). In addition, HFD increases ATM surface expression of CD11c and 
decrease CD206 (Lumeng et al., 2007). On the other hand, weight reduction was 
proved to promote the occurrence of M2-like macrophages in adipose tissue of 
obese patients (Clement et al., 2004). Although obesity has been shown to be 
associated with a shift of ATMs from M2 macrophages to M1 macrophages, the 
underlying mechanism needs to be further investigated. 
 
 
Figure 1.4  Factors important for macrophage polarization and insulin 
resistance in WAT (Olefsky and Glass, 2010).  
 




Non-alcoholic fatty liver disease (NAFLD) is a burgeoning health problem 
that affects one-third of the general population (Adams and Angulo, 2005). Used 
to be considered as a benign disease, it is now recognized as a leading cause of 
liver-related mortality and morbidity. Generally, NAFLD is defined by the 
presence of hepatic macrovesicular steatosis with less than 20g of alcohol 
ingestion per day.  It encompasses a wide spectrum ranging from simple 
triglycerides (TGs) accumulation in hepatocytes (hepatic steatosis), hepatic 
steatosis with inflammation (steatohepatitis), fibrosis, cirrhosis to 
hepatocarcinoma. NAFLD is strongly associated with obesity, insulin resistance, 
hypertension, dyslipidemia and other metabolic disorders. Thus, it is considered 
as the metabolic syndrome of the liver (Marchesini et al., 2001). 
1.5.1 Prevalence of NAFLD 
NAFLD is very common in the general population and may affect individual 
of various age and ethnic groups around the world. The prevalence of NAFLD in 
the general population reaches 14-24% (Angulo, 2002a). The percentage of 
NAFLD increases to 57.5-74 % in obese persons. In children, the percentage of 
NAFLD is 2.6% and increases to 22.5-52.8% among obese children. It is also 
estimated that non-alcoholic steatohepatitis (NASH) affects 3% of the population 
(Pettinelli et al., 2011). The increasing prevalence of NAFLD is most likely a 
result of increased prevalence of obesity, type 2 diabetes and other metabolic 
disorders in the general population (Targher et al., 2006). As such, NAFLD is 




1.5.2 Histology of NAFLD 
The main histological feature of NAFLD is the accumulation of fat in the 
form of TGs in the cytoplasm of hepatocytes. The presence of more than 5% 
steatotic hepatocytes in a liver tissue section is now accepted as the minimum 
criterion for histological diagnosis of NAFLD (Neuschwander-Tetri and Caldwell, 
2003).  
Histologically, hepatic steatosis is usually macrovesicular and characterized 
by the presence of hepatocytes containing a single large intracytoplsmic lipid 
droplet or several smaller droplets displacing the nucleus to the cell periphery. 
The steatosis might also be a mixed type with macrovesicular and microvesicular 
steatosis. Identification of pure microvescular steatosis relies on special lipid 
stains such as Oil-Red-O to identify the intracytoplasmic material as fat. 
The minimal criteria for the histological diagnosis of adult non-alcoholic 
steatohepatitis (NASH) generally include steatosis, hepatocyte injury, usually in 
the form of ballooning and lobular inflammation. However, it is still controversial 
on histologically distinguishing NASH from simple steatosis. Thus, it has been 
defined in a recent consensus conference that  NASH is the steatosis accompanied 
with hepatocellular ballooning plus lobular inflammation (Neuschwander-Tetri 
and Caldwell, 2003). Additionally, steatosis in conjunction with typical peri-
cellular/peri-sinusoidal fibrosis is also considered as NASH despite the absence of 
inflammatory features (Adams and Angulo, 2005).  
Fibrosis and architectural remodelling is thought to develop in 10%-15% of 




in acinar zone 3 and has a characteristic “chicken wire” pattern due to deposition 
of collagen and other extracellular matrix fibers along the sinusoids of zone 3 and 
around the hepatocytes. In advanced disease, bridging fibrosis and cirrhosis might 
develop (Neuschwander-Tetri and Caldwell, 2003). NASH-related cirrhosis is 
mostly macronodular or mixed. At the cirrhotic stage, perisinusoidal fibrosis and 
other features of “active” disease may or may not be evident. Therefore, in the 
absence of a previous biopsy with NASH or other disease-specific histology, 
cirrhosis may be categorized as “cryptogenic”. NASH derived cirrhosis can 
ultimately progress to hepatocellular carcinoma (HCC) (Bugianesi, 2007). In 
patients, 4 to 27% of individuals with NASH-induced cirrhosis develop HCC 
(Starley et al., 2010). 
1.5.3 Mechanism of lipid accumulation in the liver 
Hepatic steatosis is characterized by accumulation of TGs as lipid droplets in 
the cytoplasm of hepatocytes, which arises from an imbalance between lipid 
acquisition and disposal (Figure 1.5) (Ferre and Foufelle, 2010). In physiological 
conditions, the potential sources of fatty acids that contribute to hepatic TG 
formation are: (1) dietary fatty acids which arise from dietary uptake and 
metabolism of intestinal chylomicrons, (2) newly fatty acid synthesized through 
de novo lipogenesis in the liver, and (3) non-esterified fatty acids which come 
from the hydrolysis of TGs in adipose tissue. Once in the liver, fatty acids are 
esterified into TGs which can be stored in lipid droplets into hepatocytes or 




can also be hydrolysed and the released fatty acids are oxidized by mitochondrial 
β- oxidation. Therefore, increased FFA and TGs input or reduced FFA and TGs 
output can cause hepatic steatosis (Cohen et al., 2011).  
 
Figure 1.5 Mechanism of lipid accumulation in the liver (Ferre and Foufelle, 
2010). 
 
1.5.3.1 Lipogenesis and its transcriptional control 
Lipogenesis is the metabolic pathway that allows the conversion of an excess 
of carbohydrates into fatty acids. The fatty acids are ultimately esterified with 
glycerol 3-phosphate to form TGs in hepatocytes. In this process, glucose is first 
converted to pyruvate and enters the Krebs cycle in the mitochondria (Browning 
and Horton, 2004). Citrate formed in the Krebs cycle is shuttled to the cytosol and 
converted to acetyl-CoA by ATP citrate lyase. Acetyl-CoA carboxylase 1(ACC1) 
then converts acetyl-CoA to malonyl-CoA, which is used by fatty acid synthase 




desaturase (SCD) to almitoleic acid. These fatty acids are then used to synthesize 
TGs (Browning and Horton, 2004). The activity of lipogenic pathway is known to 
be strongly dependent on the nutritional conditions. A diet rich in carbohydrates 
stimulates the lipogenic pathway, whereas starvation decreases its activity. 
Carbohydrate feeding promotes de novo synthesis of FFA from acetyl–coenzyme 
A (CoA) by increasing the level of insulin and the availability of substrate. Insulin 
stimulates the transcription factor SREBP1c via a signaling cascade involving 
AKT2, LXR and mTOR (Li et al., 2010). And SREBP1c up-regulates those 
lipogenic enzymes (Horton et al., 2002). In addition, glucose also promotes 
lipogenesis by activating the transcription factor carbohydrate responsive 
element-binding protein (ChREBP). Similar with SREBP1c, ChREBP stimulates 
the expression of multiple genes involving in the fatty acid biosynthetic pathway 
mentioned above (Uyeda and Repa, 2006). 
1.5.3.2 Lipolysis  
During fasting, the decline in plasma level of insulin parallel with the 
increase in levels of glucagon and epinephrine stimulates TG hydrolysis in 
adipocytes. The first step in the process of TG hydrolysis or lipolysis is catalyzed 
by adipocyte TG hydrolase (ATGL) (Zimmermann et al., 2004). Upon hydrolysis, 
FFAs are released and transported to the liver, mostly bound to albumin. Within 
the liver, the fates of FFAs can be diversified into 3 main paths: they can be 
oxidized in mitochondria to produce energy and ketone bodies, or re-esterified to 




constituent of very-low-density lipoproteins (VLDL). Furthermore, FFAs in the 
liver can also be incorporated into phospholipids and other lipids.  
1.5.3.3 Fatty acid oxidation 
As an important metabolic tissue, the liver performs essential and complex 
metabolic processes, which requires a considerable amount of energy. The energy 
required can come from the fatty acid oxidation (FAO). The oxidation of 
intrahepatocellular fatty acid occurs primarily within mitochondria (McGarry and 
Foster, 1980). However, these fatty acids have to be activated for degradation by 
CoA, which is achieved by the formation of a fatty acyl-CoA thioester prior to its 
translocation across the membrane by a translocase. (Shindo and Hashimoto, 1978) 
Upon transport across the membrane to the matrix, carnitine acyltransferase II 
catalyzes the reattachment of the fatty acyl group to CoA, thereby reconstituting 
fatty acyl-CoA. The transport of fatty acid inside the mitochondrial matrix is 
regulated by a carnitine-dependent enzyme shuttle, sequentially carnitine 
palmitoyltransferase I (CPT-1), carnitine translocase and carnitine 
palmitoyltransferase II (CPT-2) (McGarry and Brown, 1997). Mitochondrial β-
oxidation progressively shortens the fatty acyl-CoA by two carbon units at each 
cycle (released as acetyl-CoA). This process contains a series of dehydrogenation, 
hydration and cleavage reactions that involve membrane-bound and soluble 
enzymes such as very long-chain acyl CoA dehydrogenase (VLACAD) and 
medium-chain acyl CoA dehydrogenase (MCAD) (Eaton et al., 1996). Notably, 




TG accumulation in the liver (Lewis et al., 2002). Moreover, the defect in 
mitochondrial oxidative enzymes leads to hepatic steatosis (Zhang et al., 2007). 
On the other hand, the increase in the expression or activity of hepatic enzymes 
involved in FAO reduces hepatic TG accumulation (Savage et al., 2006).  
1.5.4 The relationship between insulin resistance and hepatic steatosis  
Nonalcoholic hepatic steatosis is usually found in obese patients (Dixon et al., 
2001). Recent studies have documented a strong relationship between hepatic 
steatosis and insulin resistance which may account for hepatic steatosis in 
nonobese and even lean subjects (Lee et al., 1998; Pagano et al., 2002). NAFLD 
is also associated with other metabolic abnormalities such as glucose intolerance 
and type 2 diabetes. The coincidental occurrence of hepatic steatosis and insulin 
resistance leads to a major unresolved question over whether NAFLD is a cause 
or consequence of insulin resistance. On one hand, insulin resistance has been 
identified as a pathophysiologcial factor in the development of NAFLD such as 
hepatic steatosis. It leads to an imbalance between factors that favour hepatic lipid 
accumulation and factors that ameliorate lipid export or oxidation.  Additionally, 
the rate of lipolysis in adipose tissue is also increased under insulin resistant 
condition, which results in a net influx of FFAs into the liver which are 
subsequently converted to TGs. In particular, hyperglycemia and 
hyperinsulinemia upregulate the transcription factors of lipogenesis including 
SREBP1c and ChREBP and their targeting lipogenic genes, resulting in increased 




have shown that hepatic steatosis may also lead to insulin resistance in the liver. 
For instance, hepatic steatosis may lead to hepatic insulin resistance by interfering 
with tyrosine phosphorylation of IRS1 and IRS2 via the JNK1 pathway (Sabio et 
al., 2009). Similarly, obesity and HFD, which lead to hepatic steatosis and 
induction of NF-κB, may induce the production of inflammatory cytokines 
including TNFα and IL-6 to suppress insulin sensitivity (Shoelson et al., 2003).   
1.5.5 Diagnosis of NAFLD 
NAFLD patients are usually asymptomatic with a proportion of patients 
identified during routine health screening with the observation of elevated 
aminotransferase levels in the blood (Ramesh and Sanyal, 2005). To assess 
NAFLD, there are several diagnosis methods to be used including biochemical 
markers, imaging and examination of liver biopsy. In a patient with suspected 
NAFLD or NASH, a baseline testing including levels of AST, ALT and fasting 
serum glucose, as well as a lipid contents would be useful for diagnosis. ALT 
level is used as a surrogate marker of NAFLD in many large population-based 
studies. Higher ALT levels in blood may indicate higher risks for NAFLD 
(Amarapurka et al., 2006). However, normal ALT levels do not exclude the 
presence of NAFLD. Given that most of patients with NAFLD have other 
metabolic complications, serum levels of fasting cholesterol and TGs, as well as 
fasting glucose and insulin, should be determined to pre-diagnose the 




NAFLD can also be assessed by imaging studies including ultrasound, 
computed tomography (CT) and magnetic resonance imaging (MRI). Among 
these imaging methods, ultrasound is currently the most common method for 
screening asymptomatic patients with suspected NAFLD, particularly in obese 
patients (Mottin et al., 2004). CT provides a quantitative assessment with 
measurement of liver attenuation in Hounsfield units, which was shown to 
diagnose more than 30% of hepatic steatosis  (Schwenzer et al., 2009). In contrast, 
MRI is more sensitive and hence is able to detect early development and lower 
levels of steatosis (Fishbein et al., 2005). However, none of these imaging 
techniques has sufficient sensitivity and specificity for staging the disease and 
cannot distinguish between simple hepatic steatosis and NASH with or without 
fibrosis. Moreover, the lower availability and high cost are also the key issues for 
these imaging techniques in the assessment of NAFLD. 
Because the diagnostic accuracy of noninvasive diagnostic tools is low, 
histological examination of liver biopsy is the most reliable mean to grade the 
severity of the disease and thus estimate prognosis (Obika and Noguchi, 2012). In 
fact, liver biopsy is a golden method to determine the presence of steatosis, to 
distinguish steatosis from steatohepatitis and to assess the degree of fibrosis. 
Biopsy is also helpful in ruling out other liver diseases such as drug-induced 
hepatotoxicity, Wilson disease and autoimmune hepatitis (Angulo, 2002b). In 
addition to establishing the cause and severity of disease, histology permits the 




biopsy is costly, invasive and subject to sampling error. The search for more 
accurate and non-invasive techniques continues. 
1.5.6 Treatment of NAFLD 
Treatment of NAFLD is currently achieved by (1) improving insulin 
sensitivity by weight loss and pharmacotherapy or bariatric surgery ; (2) 
identification and treatment of associated metabolic conditions such as diabetes 
and hyperlipidaemia; (3) using hepato-protective agents such as antioxidants to 
protect the liver from secondary insults (Adams and Angulo, 2006). 
Obesity and its associated metabolic disorders such as hyperglycemia, 
dyslipidemia, type 2 diabetes increase the risk of NAFLD. Thus, the treatment of 
steatosis is inexorably associated with the treatment of obesity, diabetes and 
dyslipidemia (Tolman and Dalpiaz, 2007). Patients with newly diagnosed 
NAFLD should be screened for these conditions. Moderate amounts of weight 
loss are associated with improvement in obesity and insulin sensitivity. It is a 
widely used treatment for patients with NAFLD. Weight reduction can be 
achieved by physical exercise, restriction from dieting and bariatric surgery or 
both. While no FDA approved pharmacologic agents are applicable to directly 
treat NAFLD, emerging data on some insulin resistance- treatment drugs have 











CHAPTER 2  












2.1 Cell work 
2.1.1 Cell lines and primary cells 
Mouse 3T3-L1 cells, NIH 3T3 cells, HEK293 cells (ATCC) were cultured in 
Dulbecco's modified Eagle's medium (DMEM) (Invitrogen) supplemented with 
10% FBS (Biowest) and 1% antibiotics (Invitrogen). Mouse FL83B hepatocytes 
(ATCC) were cultured in F12K nutrient medium (Invitrogen) supplemented with 
10% FBS and 1% antibiotics. These cell lines were not cultured more than 
twenty-five passages. Primary mouse embryonic fibroblasts (MEFs) were isolated 
from WT and IRF3 KO embryos and maintained in DMEM containing 10% FBS 
and 1% antibiotics.  MEFs were not cultured more than ten passages. All cell 
cultures were maintained in a humid atmosphere of 5% CO2 at 37 °C. 
2.1.2 Establishment of stable cell lines 
To establish MKP5-overexpressed stable cell lines, F12K medium containing 
1 μg/mL of puromycin (Sigma) was added to the FL83B cells transfected with 
control plasmid or plasmid containing MKP5 coding sequence insert for the 
selection of stable cell clones. Subsequently, cell clones that survived in the 
puromycin selection medium were trypsinized and plated in 96-well microplates. 
The cells were then cultured in maintenance media containing 0.8μg/mL 
puromycin and the presence of isolated cell colonies were determined through 
visual inspection on a microscope. When cell colonies grew and reached 
confluency, they were trypsinized and further cultured in 24-well plates. Once the 




in T-25 flasks. Subsequently, MKP5 overexpression was confirmed at mRNA 
level by QRT-PCR and at protein level by Western blot analysis. The cell clones 
with MKP5 overexpression were chosen for further experiments. 
2.1.3 Isolation of mouse embryonic fibroblasts 
MEFs were isolated from 12.5~14.5 day post coitus (d.p.c.) WT and IRF3 
KO mouse embryos. Embryos were separated from maternal tissues and the yolk 
sack. After being removed amniotic sac with forceps and sever blood vessels, the 
remaining parts of bodies were minced finely with scissors and then digested in 
trypsin/EDTA (0.05% trypsin; 1mM EDTA) (Invitrogen) at 37° for 30min with 
gently mixing every 10min. The digested samples were filtered through sterile 
70μm nylon mesh for the collection of MEFs containing cell filtrate. The resultant 
MEFs were harvested by centrifugation at 1000g for 5min and cultured in DMEM 
medium containing 10% FBS and 1% antibiotics. 
2.1.4 Isolation of adipocytes and stromal vascular fraction from the white 
adipose tissue 
Adipose tissues including perigonadal fat and subcutaneous fat were 
separated from mice and then minced finely using scissors. The minced samples 
were digested in HEPES-buffer (Invitrogen) supplemented with 2.5% BSA 
(Hyclone) and 100μg/ml collagenase type II (Sigma) at 37°C on an orbital shaker 
(200rpm) for 30-60min.  After being completely digested, the cells were passed 
through a sterile 100μm nylon mesh (BD Biosciences) and the suspension was 




adipocytes. The remaining suspension was centrifuged at 1,000rpm for 1min and 
the pelleted cells were collected as the stromal vascular fractions (SVF). 
Subsequently, the supspension was transferred to new falcon tubes and 
centrifuged at 700g for 10min and collected as preadipocytes for differention.  
2.1.5 Preadipocyte differentiation 
For primary preadipocyte differentiation, preadipocytes isolated from mice 
were grown in DMEM differentiation medium supplemented with 10% new calf 
serum (NCS) (Sigma), 2.4nM insulin (Sigma) and 150μM sodium ascorbate 
(Sigma). From Day1 to Day3, the differentiation medium was changed every day. 
After that, differentiation medium were changed every 2 days until the end of the 
differentiation (Day9). The differentiated adipocytes were stained with 
BODIPY 493/503 (Sigma) and viewed under fluorescence microscope. 
For differentiation of 3T3-L1 preadipocytes into mature adipocytes, the cells 
were first grown to confluence in DMEM with 10% FCS and 1% sodium 
pyruvate (Invitrogen). Two days after reaching confluency (Day0), the culture 
medium was changed to DMEM containing with 10% FBS, 1μg/mL insulin, 
0.5mM 3-isobutyl-1-methylxanthine (IBMX) (Sigma) and 1uM dexamethasone 
(Sigma). After 2 days of differentiation induction, medium was then changed to 
DMEM supplemented with 10% FBS and 100μg/mL insulin. Finally, after 2 days, 
these cells were grown in DMEM with 10% FBS until the end of the 




For MEF differentiation, cells were first grown to confluence in DMEM with 
10% FBS. Two days after reaching confluency (Day0), the culture medium was 
changed to DMEM containing with 10% FBS, 10μg/mL insulin, 0.5 mM 3-
isobutyl-1-methylxanthine and 1μM dexamethasone and 1μM Troglitazone. The 
cells were treated with the differentiation medium for 3 days (Day3). After that, 
medium was changed to DMEM supplemented with 10% FBS, 10μg/ml insulin 
and 1μM Troglitazone. Cells were grown in this medium for 4 days (Day7). 
Subsequently, the insulin and Troglitazone were further withdrawn from the 
medium until obtaining mature adipocyte at Day9. 
2.1.6 Bone marrow derived macrophages culture  
Bone marrow derived macrophages (BMDMs) were cultured from bone 
marrow cells isolated from the bones of WT and IRF3 KO mice. After CO2 
asphyxiation, femurs and tibias were removed from mice and the ends of the 
femurs and tibias were cut and flushed with RPMI medium (Biowest) 
supplemented with 10% FBS and antibiotics using a 27G needle (Terumo). After 
being breaking into single cells using an 18G needle (Terumo), these cells were 
filtered through a sterile 70μM cell strainer (BD Biosciences) and pelleted down 
at 1100rpm for 5min. The red blood cells were lysed with 1x ACK lysis buffer. 
Cells were centrifuged and resuspended in RPMI medium supplemented with 10% 
FBS and antibiotics and 20ng/ml of macrophage colony-stimulating factor (M-
CSF; PeproTech). 5x10
6
 bone marrow cells were plated and cultured in sterile 




with 20ng/ml M-CSF on Day2, Day4 and Day6. On Day7, the macrophages were 
stained for CD11b positivity. The BMDMs were then seeded in 6 or 12-well 
plates for further experiments. 
2.2 Mice work 
2.2.1 Maintenance of mice 
All animal protocols were approved by the Animal Care and Use Committee 
of National University of Singapore. All mice under C57BL6/J genetic 
background were housed under a 12:12-h light-dark cycle and an ambient 
temperature of 22°C and allowed free access to water and food. Beside WT mice, 
two kinds of transgenic knockout mice, IRF3 KO mice (kindly provided by Dr. 
Stephan Gasser from National University of Singapore) and MKP5 KO mice were 
used in this study. Oxymax/CLAMS (Columbus Instruments) was used to 
quantify food intake, oxygen consumption (VO2), carbon dioxide production 
(VCO2) and respiratory exchange ratio (RER) of individual mice for 5 days at the 
Laboratory of Metabolic Medicine, Singapore. Energy expenditure of the mice 
was calculated with the formula [(3.815 + 1.232 xVCO2/VO2) x VO2 x 0.001]. 
For diet studies, seven to nine week old C57BL6/J mice were fed with high fat 
diet diet (35% Lard Diet) purchased from Harlon Laboratories. In the p38 
inhibitor treatment experiment, mice were first placed on high fat diet feeding for 
2 weeks before oral administration of p38 inhibitor SB203580 (4-(4-
fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4- pyridyl)imidazole) (Calbiochem)  





The genotyping of mice was determined using genomic DNA was isolated 
from mouse tails. Mouse tails tips were digested in tail lysis buffer containing 
0.24mg/mL proteinase K (Promgega) at 55°C overnight. Subsequently, the tail 
lysate samples were centrifuged at maximum speed for 10min and the supernant 
were transferred to new eppendorf tube. The equal volume of 100% ethanol was 
added to each tube and mixed gently to precipitate the DNA. After spinning, the 
supernatant were removed and the DNA pellet was rinsed with 70% ethanol. 
Finally, the DNA was left to air dry before suspension in 100μl of TE buffer 
(10mM Tris-Cl, pH 7.5, 1mM EDTA) at room temperature.  
The mice genotyping was done by PCR amplification with the condition of 
40 cycles of 94ºC for 30s, 60ºC for 30s, 72ºC for 30s. For WT and IRF3 KO 
genotyping, the WT allele (350bp) was amplified by primers: WT-FWD, 
GAACCTCGGAGTTATCCCGAAGG; WT-RVS, 
GTTTGAGGTATCCCTGCACTTGGG. The IRF3 KO allele (450bp) was 
amplified by the primers: IRF3-FWD, GAACCTCGGAGTTATCCCGAAGG; 
IRF3-RVS, TCGTGCTTTACGCTATCGCCGCTCCCGATT. 
2.2.3 Samples collection  
Mice were anesthetized with CO2. Blood was collected via cardiac puncture 
and kept in microcentrifuge tube on the ice. After spinning at 3000rpm for 20min, 
the serum from the blood samples were transferred into new tube and stored at –




subcutaneous fat depots, brown adipose tissue, skeletal muscles and livers were 
excised and rinsed in saline to remove residual blood. The tissues were distributed 
accordingly for downstream processes in the appropriate buffer including: (1) in 
Trizol for RNA extraction, (2) in 10% neutral formalin for histological analysis, 
(3) frozen in O.C.T. for lipid droplets staining and (4) frozen at -80°C for 
biochemical analysis. 
2.2.4 Histology 
2.2.4.1 Hematoxylin and eosin staining 
Tissues including adipose tissues and livers were fixed in 10% neutral 
buffered formalin, paraffin embedded and cut into sections of 5μm thickness. The 
paraffin- embedded tissue sections were deparaffinized in histoclear clearing 
agent (Sigma) three times for 5min each. The tissue sections were then rehydrated 
with 5 changes of ethanol with reducing concentration (100%, 100%, 95%, 80%, 
70%) for 3min each. The sections were then rinsed in PBS. For hematoxylin and 
eosin staining, the slides were stained with Mayer hematoxylin for 30min and 
then rinsed with running water until water dripping off the slide was clear. Then 
the slides were stained with eosin for 1min and rinsed with running water until the 
water dripping off the slide was clear. After each of the staining, the slides were 
dehydrated in 5 changes of increasing concentration of ethanol (70%, 80%, 95%, 
100%, 100%) and 2 times of histoclear for 3min each. Finally, sections were 
mounted using mounting medium (Invitrogen) and dried in a fume hood until 




2.2.4.2 Immunohistochemistry (IHC) 
For IHC, the rehydrated slides from paraffin embedded samples were 
transferred into a coplin jar filled with 10mM citric acid (antigen retrieval solution) 
and boiled for 10min. After that, the slides were allowed to cool down to room 
temperature before endogenous peroxidase activity was blocked using 3% 
hydrogen peroxide for 5min. Subsequently, non-specific sites on the tissue were 
blocked with 3% BSA and the primary antibody against F4/80 was applied to the 
sections and incubated overnight in a humidified chamber. On the following day, 
the tissue sections were rinsed with PBS for 3 times, 5min each and horseradish 
peroxidase (HRP)-conjugated secondary antibody (eBioscience) was applied to 
the slides for 30min. Then, the slides were rinsed in PBS for 5min and the DAB 
chromogen substrate was applied for 5min or until the desired colour intensity 
was achieved. The slides were then dehydrated and mounted with mounting 
medium described in section 2.2.4.1 above. 
2.2.4.3 Oil Red O staining of cyro-sections 
Livers were removed from mice and rinsed with saline before being 
embedded in Tissue Tek (Electron Microscopy Sciences) and stored at -80°C. 
Livers were cut into 8μm thick sections and then placed on polysine-coated slides. 
The sections were then kept frozen at –20°C until analysis. To perform Oil Red O 
staining, liver sections were wet with dH2O and incubated in Oil Red O working 
solution (0.3% Oil Red O (Sigma) in 60% isopropanol) for 1h. After that, slides 




isopropanol dripping off the slides was clear. Subsequently, the slides were 
washed with H2O followed by incubation in hematoxylin to stain nucleus for 
5min. The sections were then blued in running tap water for 10min and rinsed 
with deionised water. Excess water was drained onto a paper towel. The slides 
were mounted in glycerin jelly (Sigma) and dried in a fume hood until ready for 
analysis. 
2.2.5 Blood biochemical study  
2.2.5.1 Glucose and insulin tolerance tests 
Glucose tolerance tests (GTT) were performed by intraperitoneal injection 
(i.p.) of glucose (1.5g/kg) to mice whereas insulin tolerance tests (ITT) were 
conducted by i.p. injection of recombinant human insulin (0.7unit/kg) (Sigma) to 
mice. Tail blood samples were taken before (0min) and 15, 30, 60, 90,120min 
after injection of glucose or insulin. The blood glucose level was measured using 
the Accu-Chek glucometer and Accu-Chek test strips (Roche) with appropriate 
calibration. Mice were fasted for 16h and 2h for GTT and ITT, respectively. 
2.2.5.2 Blood parameters 
Blood was collected by cardiac puncture after mice were euthanized with 
CO2 or from tail bleeds. Serum was harvested from whole blood by centrifugation 
for 20min at 3000rpm and aliquoted for storage at –80°C. Triglycerides were 
measured using triglyceride determination kit (Sigma) based on manufacturer’s 
instructions. Cholesterols were measured by using cholesterol determination kit 




In addition, serum insulin and adiponectin levels were measured using ELISA kits 
(Millipore). Levels of fasting blood glucose were measured using calibrated 
Accu-Chek glucometer.   
2.2.6 Lipid extraction and determination from livers 
Lipids from liver tissues were extracted using the methanol-
chloroform method. Snap-frozen liver fragments of equal weight were 
homogenized in nine volumes of PBS. 200μl of the homogenate was transferred 
into 1,200μl of chloroform:methanol (2:1; v/v) mixture and mixed vigorously for 
30s. 100μl of PBS was then added and the resulting suspension was mixed 
vigorously for 15s and centrifuged at 4,200g for 10min at 4 °C. 200μl of the 
organic phase at the bottom was transferred into a tube and left to dry in the fume 
hood. The dried lipid residue was resuspended in 100μl of 1% Triton X100 
(Sigma) in absolute ethanol for 4h. Levels of hepatic triglyceride, cholesterol and 
NEFA were determined with the respective determination kit stated in section 
2.2.5.2 above. 
2.2.7 Immunostaining and flow cytometry 
The SVF isolated from mouse adipose tissue were centrifuged at 400g for 
5min. The pellet was resuspended in FACS buffer (1%BSA in PBS) and counted 
using a hemocytometer. After blocking with FcR Blocking Reagent, cells were 
incubated with fluorophore-conjugated primary antibodies for 1h.  The primary 
antibodies used in the studies included: CD45.2-PE, CD45.2-APC, CD45.2-PCP, 
F4/80
+




washed with FACS buffer twice. Finally, cells were resuspended in FACS buffer 
and performed flow cytometry analysis using FACS Calibur. Data analysis was 
performed using Flow Jo software (Treestar). Appropriate gating was used to 
determine the cells of interest.  
2.3 Human adipose tissue collection and analysis 
Twenty-eight subcutaneous adipose tissue samples from a group of morbidly 
obese (BMI > 35 kg/m
2
) caucasian subjects with different degrees of insulin 
action [measured using hyperinsulinemic-euglycemic clamp (Moreno-Navarrete 
et al., 2013) recruited at the Endocrinology Service of the Hospital University Dr. 
Josep Trueta (Girona, Spain) were studied. All subjects reviewed that their body 
weight had been stable for at least 3 months.  They had no systemic disease other 
than obesity and all were free of any infections in the previous month before the 
study. Liver disease and thyroid dysfunction were specifically excluded by 
biochemical work-up. All subjects gave written informed consent after the 
purpose, nature and potential risks for the study were explained to them. The 
Hospital Ethics Committee approved the protocol. Adipose tissue samples were 
obtained during elective surgical procedures (cholecystectomy, surgery of 
abdominal hernia, and gastric by-pass surgery), washed, fragmented and 
immediately flash-frozen in liquid nitrogen before being stored at -80ºC.  
RNA purification and gene expression procedures and analyses were 
performed as previously described in section 2.5.1. Gene expression was assessed 




Diagnostics SL), using TaqMan® technology suitable for relative genetic 
expression quantification. The commercially available and pre-validated 
TaqMan® primer/probe sets used for gene expression analyses (Life 
technologies): IRF3 (Hs01547282_m1), IRS1 (Hs00178563_m1), GLUT4 or 
SLC2A4 (Hs00168966_m1), PPIA (Housekeeping. Hs99999904_m1). 
Glycosylated haemoglobin (HbA1c) was measured by the high-performance 
liquid chromatography method (Bio-Rad, Muenchen, Germany, and autoanalyser 
Jokoh HS-10, respectively). Intra- and inter-assay coefficients of variation were 
less than 4% for all these tests. 
2.4 Protein work 
2.4.1 Cell lysates preparation and protein quantification 
Cells were harvested and lysed in cell lysis buffer (20mM Tris, 100mM NaCl, 
1% NP-40 and proteinase inhibitors & phosphatase inhibitors cocktail (Roche)) 
after the indicated time of designated treatments. After spinning at 13,200rpm for 
10min, clear protein lysate was transferred to new tubes and protein concentration 
of the samples was quantified by bradford assay (Bio-Rad Laboratories) based on 
manufacturer’s instructions. Briefly, 10μL of appropriately diluted protein lysate 
were mixed with 200μl 1X bradford reagent and then incubated at room 
temperature for 5min. The absorbance was using the BioTek® Synergy H1 
Hybrid Multi-mode Microplate Reader at wavelength 595nm. Protein 





2.4.2 Western blot 
Protein samples were mixed with appropriate volume of 4× protein loading 
dye and boiled at 95°C for 10min to denature protein. Denatured samples were 
then loaded into subsequent wells of gels and sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) was performed at 80V for 
20min for proteins to cross the stacking gel before voltage was adjusted to 140V 
for 1h to separate different sizes of protein in the gel. In this study, 8-12% 
Tris/Glycine resolving gel and 5% stacking gel were used for the analysis of 
different molecular weight proteins. 
After SDS-PAGE, protein was transferred from gel onto 0.2μm 
polyvinylidene fluoride (PVDF) membrane (Bio-Rad Laboratories) at 4°C. After 
transfer of protein to PVDF membrane, the membrane was blocked with 5% milk 
(Anlene)  in TBST for 1h at room temperature on an orbital shaker. Subsequently, 
the membrane was incubated in primary antibody at 4°C overnight at indicated 
dilution using blocking buffer. The primary antibodies used were: phosphor-IRF3 
Rabbit polyclonal antibody, IRF3 Rabbit monoclonal antibody, PPARγ Rabbit 
monoclonal antibody, C/EBPα Rabbit monoclonal antibody, phosphor-
AKT(Ser473) Rabbit monoclonal Rabbit antibody, AKT Rabbit monoclonal 
Rabbit antibody, Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204), Rabbit 
monoclonal antibody, Phospho-SAPK/JNK (Thr183/Tyr185) Rabbit monoclonal 
antibody, Phospho-p38 MAPK (Thr180/Tyr182) Rabbit monoclonal antibody 
(The antibodies above were purchased from Cell Signaling Technology, USA) 




FSP27 Rabbit polyclonal antibody (These antibodies were purchased from 
Abcam). After overnight incubation, membranes were washed with TBST for four 
times at 10min each. Subsequently, membranes were incubated with secondary 
antibody(1:4000) diluted with blocking buffer at room temperature for 1h. The 
secondary antibodies used in the study were Amersham ECL anti-mouse IgG, 
horseradish peroxidase-linked species-specific whole antibody (from goat) (Santa 
Cruz) and anti-rabbit IgG, horseradish peroxidase-linked species-specific whole 
antibody (from donkey) (GE Healthcare). After incubation, membranes were 
subsequently washed with TBST four times at 10min each. Finally, membranes 
were treated for chemiluminescence detection using Supersignal West Dura 
Extended Extended Duration Substrate (Thermo). Luminescence was detected 
using Kodak Image Station 440CF (Kodak) and Amersham hyperfilm MP ECL 
autoradiography film (GE Healthcare) and processed using X-ray film processor 
(Kodak). 
2.4.3 Enzyme-linked Immuno-Sorbent Assay (ELISA) 
The concentration of pro-inflammatory cytokines, IL-6 and TNFα secreted 
into culture supernatant of unstimulated or stimulated BMDMs were determined 
by ELISA. A 96 well ELISA plate was coated with 100μl/well of 1ug/ml purified 
rat anti-mouse monoclonal antibody (BD Pharmingen) and incubated overnight at 
4°C. After washing with PBST (1x PBS containing 0.05% Tween20), 5% BSA 
blocking solution was added to the wells to block the non- specific protein 




added at 100μl/well in replicates. Murine IL-6 or TNFα standards (PeproTech) 
were prepared in serially 2X dilution, each with duplicates. After incubation at 
37°C for 3h hours or 4°C overnight, the wells were washed with PBST for six 
times and incubated with 100μl of 0.5μg/ml biotinylated rat anti-mouse 
monoclonal antibody (BD Pharmingen) for 1h at room temperature. Avidin-HRP 
conjugate (BioLegend) was then added and incubated for 1h at room temperature 
followed by six times wash with TBST.  Subsequently, 100μl of the Sigma Fast 
OPD (o-phenylenediamine dihydrochloride) (Sigma) was added followed by 
adding 50μl of the stop solution (4.5N H2SO4) when proper colour was developed. 
The absorbance at 490nm was read with BioTek® Synergy H1 Hybrid Multi-
mode Microplate Reader. Concentration of certain cytokines was calculated 
according to the standard curve. 
2.5 RNA work  
2.5.1 Total RNA extraction and reverse transcription-PCR 
Total cellular RNA was extracted from cells using Trizol method (Invitrogen). 
Cells were harvested, kept in 1ml Trizol reagent and stored at -80°C until analysis. 
200μl of chloroform (Sigma) was added into Trizol sample followed by shaking 
vigorously and spinning at 13,200rpm for 15min. RNA in the aqueous phase 
(upper layer) was transferred into new tube and precipitated by mixing with 1 
volume of isopropanol (Sigma) and centrifuged at 13,200rpm for 10min to pellet 
the RNA. The resultant RNA pellet is further washed with ice cold 75% ethanol 
before drying and resuspension in 20μl of DEPC-treated water (Invitrogen). Total 




according to the manufacturer’s protocol.  Concentration of RNA was determined 
using BioTek® Synergy H1 Hybrid Multi-mode Microplate Reader.  
Reverse transcription was performed using ImProm-IITM Reverse 
Transcription System (Promega).  A total of 2μg RNA and with 1μl of Oligo 
(dT)15 Primer were added into PCR tube for denaturation at 70°C for 5min. The 
reaction mixture was subsequently added to 15μl of mixture containing 4.2μl of 
nuclease free water, 4μl of ImProm-II 5X reaction buffer, 4.8μl of MgSO4 
(Promega), 1μl of dNTP mix (Promega) and 1μl of ImProm-II Reverse 
Transcriptase. The reverse transcription mixture was then subjected to cycling 
conditions of 25°C for 5min, 42°C for 60min and lastly enzyme deactivation at 
70°C for 15min. 
2.5.2 Quantitative Real-Time PCR  
Quantitative real-time PCR (QRT-PCR) was performed using Fast-SYBR® 
Green Master Mix (Bio-Rad Laboratories). Each reaction was prepared with 5ul 
Fast-SYBR® Green Master Mix, 1ul of appropriately diluted cDNA, 1ul forward 
& reverse primers and 3ul H2O. The QRT-PCR program was 95˚C for 30s 
followed by 40 cycles of 5s at 95˚C and 20s at 60˚C. Melting curve analysis was 
done after 40 cycles to examine specificity of the amplified products. Relative 
quantification of mRNA levels was calculated by the ΔΔCT method.  
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was the endogenous 





Table 2.1 Sequence of primers used for quantitative QRT-PCR 
Gene name Forward sequence Reverse sequence 
Adiponectin GTTGCAAGCTCTCCTGTTCC GCTTCTCCAGGCTCTCCTTT 





Cebpδ TTCCAACCCCTTCCCTGAT CTGGAGGGTTTGTGTTTTCTGT 
Glut4 GATTCTGCTGCCCTTCTGTC ATTGGACGCTCTCTCTCCAA 
Scd1 CGCCCAAGCTGGAGTACGTC GGGCCCATTCGTACACGTCA 
Plin1 GATCGCCTCTGAACTGAAGG CTTCTCGATGCTTCCCAGAG 
Fgf1 GTGGATGGGACAAGGGACAG TCTGGCCATAGTGAGTCCGA 
Ffg2 GCGACCCACACGTCAAACTA TCCCTTGATAGACACAACTCCTC 
Ffg10 GAAGGCATGTGCGGAGCTA TGGCTTTGACGGCAACAACT 
Ffg18 CCTGCACTTGCCTGTGTTTAC TGCTTCCGACTCACATCATCT 
Ffg21 CTGCTGGGGGTCTACCAAG AAACCTAGAGGCTTTGACAC 
Cfd CATGCTCGGCCCTACATGG CACAGAGTCGTCATCCGTCAC 
Adhfe1 GAGGCACCTACAAAGCACAG CCATCTCAAAGGCGTAATCTGC 
Aqp7 AATATGGTGCGAGAGTTTCTGG ACCCAAGTTGACACCGAGATA 
Acaa1b CAGGACGTGAAGCTAAAGCCT CTCCGAAGTTATCCCCATAGGAA 
Ppargc1b TGACGTGGACGAGCTTTCAC CTTTCACTCTGGGACAGGGC 
Cpt1b GCACACCAGGCAGTAGCTTT GATGCAATCGACCAGTCCCA 
Glu1 TGAACAAAGGCATCAAGCAAAT GGAAGGGGTCTCGAAACATGG 
Fabp5 AAAGAGCTAGGAGTAGGACTGG TGTTGCCATCACACGTAATGA 
SREBP1c CTGGAGACATCGCAAACAAGC ATGGTAGACAACAGCCGCAC 
PPARγ ATCTTAACTGCCGGATCCAC AGGCACTTCTGAAACCGACA 
ACC1 GAAGTCAGAGCCACGGCACA GGCAATCTCAGTTCAAGCCAGTC 
ACC2 CATGGTAGTGGCTTTGAAGGA CGTGTCGATATCGTTGTTCTG 
Fasn AGTGTCCACCAACAAGCG GATGCCGTCAGGTTTCAG 
DGAT1 TTCCGCCTCTGGGCATT AGAATCGGCCCACAATCCA 
IL-6 ATGAAGTTCCTCTCTGCA TGTACTCCAGGTAGCTATG 








ATGL CTTCCTGGTGGCCAACGCCACT GCAGATGTCACTCTCGCCTG 
HSL GGAGCACTACAAACGCAAC TCCCGTAGGTCATAGGAGAT 
Cidea TGACATTCATGGGATTGCAGAC GGCCAGTTGTGATGACTAAGAC 
Cideb CAATGGCCTGCTAAGGTCAGT GATCACAGACACGGAAGGGTC 
Fsp27 GTGTTAGCACCGCAGATCG  CACGATTGTGCCATCTTCC 
GAPDH GACAACTTTGGCATTGTGG ATGCAGGGATGATGTTCTG 
 
2.5.3 Microarray analysis 
Microarray analysis was performed using affymetrix microarray system 
(Affymetrix) serviced by Sciencewerke Pte Ltd. The analysis was conducted by 
our collaborator A/Prof Henry YANG. 
2.6 Luciferase reporter assay 
NIH3T3 cells (1.5 x 10
5
 cells) or FL83B cells (1 x 10
5
 cells) were seeded into 
each well of a 24-well plate before transfection. NIH3T3 cells were co-transfected 
with 100ng of reporter constructs and vector containing IRF3 cDNA or control 
vector together with 10ng of pRL-CMV Renilla luciferase control plasmid using 
Lipofectamine LTX (Invitrogen) or TransIT-3T3 transfection reagents (Mirus). 
FL83B cells were co-transfected with 500 ng of reporter constructs and vector 
containing MKP5 cDNA or control vector together with 10ng of pRL-CMV 
Renilla luciferase control plasmid using Lipofectamine LTX reagents. When 
Lipofectamine LTX was used for transfection, the transfection solution was 
replaced with DMEM 6h post addition of the transfection complex. Treatment of 
Troglitazone or palmitic acid was performed according to the requirement of 




with 1 x Passive Lysis Buffer for 15min. The cell lysate was transferred into a 
fresh tube and used immediately or kept in -80 °C freezer. Luciferase assay was 
conducted using the Dual-Luciferase Reporter Assay System (Promega) 
according to the manufacturer’s instructions. The firefly luciferase activity was 
normalized to that of renilla luciferase activity for each well and the data was 
presented as relative luciferase activity. 
2.7 Chromatin immunoprecipitation (ChIP) assay 
Mouse hepatocytes FL83B cells and MKP5 overexpression FL83B cells were 
treated with palmitic acid and were subsequently cross-linked by adding 37% 
formaldehyde to 1% final concentration and being shaked on orbital shaker for 
10min. Cross-linking was terminated by adding 2M glycine to 125mM final 
concentration. After being washed with ice cold PBS, cells were harvested in cold 
PBS and pelleted for lysis in cell lysis buffer containing protease inhibitors at 4°C 
for 10min. After centrifugation, nuclei were collected and resuspended in nuclear 
lysis buffer containing the protease inhibitor cocktail at 4°C for 10min. The 
chromatin was sheared with vibra-cell sonicator, set at 30% amplitude, for 10 X 
30s with 60s interval between each cycle. The sonicated lysate were centrifuged 
and supernatant was used for immune-precipitation. The shared chromatin was 
incubated with 80μL of protein A sepharose (Amersham Biosciences) at 4 °C for 
30min. The chromatin solutions were divided into aliquots to assay with different 
antibodies. For each immune-precipitation, 5% of the aliquots were saved as input, 




antibody or control IgG. The immune complex was pulled down through 
incubation with 60μL of protein A sepharose at 4 °C for 1h. After that, the beads 
were washed with low salt wash buffer and high salt wash buffer at 4°C, LiCl 
wash buffer and Tris–EDTA at room temperature. Finally, the immunocomplex 
was eluted from the beads using 500μL elution buffer at 60°C for 30min. Cross-
links were reversed by further incubation at 65°C for 8h, followed by 1h 
incubation with 8μl of Proteinase K (20mg/ml) and 1h incubation with 2μl of 
RNAseA (10mg/ml) to remove proteins and RNAs. DNA were extracted by 
phenol:choloroform and precipitated with ethanol. DNA pellet were resuspended 
in water for QRT-PCR with the following primers shown in table 2.2. 
Table 2.2 Sequence of primers used in ChIP experiment 
Gene name Forward sequence Reverse sequence 
Cidea ATAGGACCCTCCTCCATCCG CTCCCCTTCTGCTCCCTAGT 
Cideb AAGTGCCTGGACAGCTTTGT TGATTGGTGCCTGAAGTGGC 
Fsp27/Cidec CCCGTGGAGTTTCTGGACTA AGTCAGTGCTAAAGAGGCCC 
2.8 Molecular cloning work 
2.8.1 Preparation of competent cells 
E.coli competent cells were prepared using calcium chloride treatment 
method.  A single E.coli colony from a culture plate was grown in LB broth 
overnight. 5mL of E.coli culture was inoculated into 500mL LB broth and grown 
in 37°C shaker. When OD600 reached 0.4~0.5, E.coli culture was placed on ice 




The pellet was resuspended in about 100mL of ice cold MgCl2 and centrifuged at 
2000g for at 4°C 15min. Subsequently, the pellet was resuspended in 200mL of 
ice cold CaCl2 and kept on ice for 30min. After centrifugation at 2000g at 4°C for 
15min, the pellet was resuspended in 50mL ice cold 85mM CaCl2 containing 15% 
glycerol and all the suspension was transferred into a new 50mL falcon tube. 
Finally, the cells were harvested by centrifugation at 1000g at 4°C for 15min and 
resuspended in 5mL ice cold 85mM CaCl2 containing 15% glycerol. 50μL of 
competent cells was aliquoted into sterile 1.5mL tubes and snap frozen with liquid 
nitrogen. All the competent cells were then stored at -80°C until use. 
2.8.2 General cloning protocols 
2.8.2.1 Insert preparation 
The insert DNA was amplified by PCR using cDNA or genomic DNA from 
mouse as templates. PCR product was purified using a PCR product clean kit 
(Qiagen) and further used for restriction enzyme digestion. In digestion reaction, 
5ug of purified DNA was usually used for to get sufficient insert DNA after 
digestion followed by purification.  
2.8.2.2 Vector preparation 
5μg of parental vector DNA was digested in a 100μl of reaction by incubating 
with appropriate enzyme(s) from promega. In single enzyme digestion reaction, 
calf intestinal alkaline phosphatise (CIP) (Promega) was further added for 
dephosphorylation to prevent self-ligation of vector. After digestion, the vector 




2.8.2.3 Ligation and transformation 
Ligation reaction was carried out in a 20μl of total volume containing T4 
DNA ligase, 1X ligase buffer and appropriate amount of vector and insert DNA. 
The ligation mixture was incubated overnight at 16°C for ligation. 
For transformation, 50μl of competent cells were first thawed on ice for 
20min. Subsequently, 5-10μl of ligation product was added into competent cells, 
mixed gently and incubated on ice for 20min. The cell mixture was then 
performed a heat shock at 42°C for 90s followed by 5min incubation on ice. Then 
1mL of LB broth or SOC (Invitrogen) was added into the transformation mixture 
and cultured at 37°C for 1h. Finally, the bacteria was plated on LB agar plate 
containing indicated antibiotic and incubated at 37°C overnight.  
2.8.2.4 Screening for positive transformants 
The preliminary screening of transformants was performed by PCR followed 
by a restriction enzyme digestion analysis. Several colonies were picked out and 
inoculated into 3mL LB medium supplemented with antibiotics. The culture was 
grown at 37°C overnight with shaking. 0.5ml of the culture was harvested by 
centrifuging at 5,000rpm for 1min and re-suspended with 50μl H2O followed by 
heating at 95°C for 5min. Then PCR was carried out with cloning primers. In the 
PCR reaction, 1μl of the mixture above was used as the template. The remaining 
cell mixture was pellet down for further plasmid purification using Minipreps 
DNA purification system (Axygen) according to the manufacturer’s instructions. 




restriction enzyme digestion reaction and digested DNA samples were separated 
on 1-1.5% agarose gel. 
2.8.3 Construction of plasmids 
Several different vectors were used for the construction of plasmids in this 
study (Figure 2.1 and 2.2). pcDNA3.1-IRF3 recombinant was constructed by 
cloning mouse IRF3 encoding region into EcoR I site of the pcDNA3.1(-) (Figure 
2.1).  pcDNA3.1-MKP5 recombinant was constructed by cloning mouse MKP5 
encoding region into EcoR I and BamH I sites of the pcDNA3.1(-).  pGL3-Cidea 
and pGL3-Fsp27 luciferase recombinant were constructed by cloning promoter 
regions of mouse Cidea and Fsp27/Cidec into Nhe I & Xho I and Kpn I & Sac I  
sites of pGL3-basic. PPY-MKP5 was constructed by subcloing MKP5 encoding 
region from pcDNA3.1-MKP5 into PPY vector. 
Table 2.3 Sequence of primers used for cloning work 






























Figure 2.1 Map of the pcDNA3.1(-) vector. The map shows the main features of 




Figure 2.2 Map of pGL3-Basic Vector. The map shows the main features of this 






Figure 2.3 Map of PPY vector. The map shows the main features of this vector 
and the multiple cloning sites (MCS).  
2.9 Statistical analysis  
The image data were representatives of 2 to 3 independent experiments with 
similar results. The quantification of image figures was perfomred using Image J 
software. Mice work was performed using 3-5 mice per group per time and data 
were representatives of 2 to 3 repeated experiments with similar results. All 
numeric values were presented as mean ± S.E.. The p-value was calculated using 















































CHAPTER 3  
REGULATION OF INFLAMMATION AND METABOLISM 













3.1.1 Interferon regulatory factors 
Interferon regulatory factors (IRFs) constitute a family of nine transcription 
factors (IRF1 to IRF9) in mammals (Savitsky et al., 2010). All IRF proteins share 
homology in their N-terminal DNA-binding domains of about 120 amino acids. 
This region forms a helix-turn-helix motif and recognizes a consensus DNA 
sequence, known as the IFN-stimulated response element (ISRE or IRF-E) that 
was first identified in the promoters of genes that were induced by type I IFNs 
(Platanias, 2005; Taniguchi et al., 2001). IRF3, a member of the IRF family, was 
originally discovered as a homologue of IRF1 and IRF2 (Lin et al., 1999b). The 
IRF3 protein was found to contain several functional domains including the 
nuclear localization sequence (oblique bars), the nuclear export signal (hatched 
box), a DNA-binding domain (DBD), a C-terminal IRF association domain (IAD), 
proline rich sequence (Pro), the signal response domain (RD) and several 
regulatory phosphorylation sites (Figure 3.1.1)  (Lin et al., 1999a; Servant et al., 
2002). In unstimulated cells, IRF3 is present in the cytoplasm as an inactive form. 
Upon viral infection or other stimulation, phosphorylation of serine/threonine on 
IRF3 occurs. This leads to IRF3 dimerization and subsequent interaction with the 
coactivators CREB-binding protein (CBP) and p300 to form a complex. This 
complex translocates into the nucleus and activates the transcription of IFNα and 
IFNβ, as well as other interferon-induced genes (Fitzgerald et al., 2003; 





Figure 3.1.1 Schematic representation of IRF3 structural domains (Servant et 
al., 2002) 
 
The phosphorylation and activation of IRF3 in response to virus infection and 
other stimulation such as cellular stress can be mediated by multiple signalling 
pathways. In Toll-like receptor (TLR) signalling pathways, IRF3 can be activated 
by TBK1 or IKKε or both independent of MyD88, leading to the production of 
IFN-β and the expression of IFN-inducible genes upon viral infection or LPS 
stimulation. This process depends on TRIF  (Takeda and Akira, 2005). Cellular 
stress or stress-inducing reagents also functionally induce IRF3 activation. A 
study by Kim et al. has demonstrated that stress inducer CG18 stimulated the 
activation of MEKK1 that led to IRF3 activation through the JNK pathway but 
not through p38 or IKK pathways (Kim et al., 2000). Recently, endoplasmic 
reticulum stress has been found to induce IRF3 activation by different 
mechanisms according to the type of ER stressor. Some forms of ER stress, in 
particular those that involved calcium mobilization,  require STING and TBK1 
for IRF3 activation and nuclear translocation (Liu et al., 2012). In contrast, other 
ER stress inducer may activate IRF3 by a pathway inhibited by 4-(2-aminoethyl)-




prevents UPR-dependent processing of ATF6 (Liu et al., 2012). So far, the 
activation of IRF3 by various signaling pathways is not fully understood. Thus, it 
is of great importance to understand the mechanisms by which IRF3 was activated 
in response to a variety of stimulation or under different conditions as this may 
provide the basis for the regulation of proper activity of IRFs. 
3.1.2 Functions of IRFs in metabolism 
In the past decades, IRFs were mainly implicated in the regulation of many 
immune processes, including anti-viral innate immunity, B-cell development and 
function, dendritic cell development, inflammation and Th1-cell responses 
(Honda and Taniguchi, 2006; Lau et al., 2008). Besides, IRFs were also found to 
play important roles in the regulation of malignant transformation through 
regulating cell growth and apoptosis (Takaoka et al., 2008). Interestingly, there 
are accumulating evidence supporting the important roles of IRFs in regulating 
metabolism recently. 
IRFs was first identified by Eguchi and his colleagues as important regulators 
of adipogenesis during an unbiased search for novel transcriptional regulators 
based on DNase hypersensitivity (Eguchi et al., 2008). In this study, all IRFs were 
found to be expressed in adipose tissue. With the exception of IRF5, all of the 
IRFs had higher expression in resident macrophages compared with that in 
adipocytes. During 3T3-L1 pre-adipocyte differentiation, all IRFs were 
developmentally regulated with three distinct expression patterns: (1) most IRFs 




their expression was then repressed early after the induction of differentiation 
before being re-expressed in mature adipocytes; (2) the expression of IRF3 and 
IRF4 was induced during differentiation; (3) IRF5 was highly expressed in pre-
adipocytes but receded as adipogenesis proceeded (Eguchi et al., 2008). 
Knockdown of IRFs individually in 3T3-L1 pre-adipocytes experiments showed 
that silencing of IRF1, IRF3 and IRF4 led to elevated lipid accumulation 
associated with enhanced adipocyte gene expression during adipocyte 
differentiation (Eguchi et al., 2008). This indicates that IRF1, IRF3 and IRF4 may 
negatively regulate adipogenesis. 
Using a gene knockout mice model, the functions of IRFs in energy 
metabolism were further explored. After discovering the regulatory roles of IRFs 
in adipogensis, Eguchi et al. found that IRF4 not only transcriptionally controlled 
adipose lipid handling in adipocytes but also regulated obesity-induced 
inflammation through controlling ATM polarization (Eguchi et al., 2013; Eguchi 
et al., 2011). In adipocytes, the expression of IRF4 was nutritionally regulated, 
which was mediated through the action of insulin on Forkhead box protein O1 
(FoxO1). In addition, conditional knockout of IRF4 in adipocytes led to increased 
adiposity and impaired insulin sensitivity and glucose homeostasis, which was 
associated with diminished lipolysis in adipocytes, indicating that IRF4 positively 
regulates lipolysis in adipocytes (Eguchi et al., 2011). The higher expression of 
IRF4 in resident macrophages in adipose tissue also led Eguchi and his colleagues 
to explore the functional role of IRF4 in ATMs in obesity.  They found that IRF4 




IL-6 and TNFα (Eguchi et al., 2013). Co-culture of IRF4 KO macrophages with 
adipocytes reduced insulin sensitivity as compared with co-culture of WT 
macrophages with adipocytes. Additionally, mice with a deficiency of IRF4 in 
macrophages exhibited insulin resistance (Eguchi et al., 2013). Together, they 
concluded that IRF4 regulates insulin sensitivity through its actions on both 
adipocytes and macrophages within WATs. 
Recently, the role of IRF7, IRF9 and IRF3 in metabolism was also described 
in detail (Wang et al., 2013a; Wang et al., 2013b; Wang et al., 2013c). Studies 
have shown that IRF7 KO mice were resistant to develop obesity and displayed 
improved insulin sensitivity and glucose homeostasis compared with WT controls 
upon HFD feeding (Wang et al., 2013c). Furthermore, IRF7 KO mice were more 
susceptible to diet-induced hepatic steatosis. In another mouse model, IRF9 was 
revealed to play an important role against metabolic disorders such as insulin 
resistance. After HFD feeding, mice deficient in IRF9 had higher levels of 
obesity-induced inflammation, lower insulin sensitivity and more severe hepatic 
steatosis than WT controls (Wang et al., 2013a). In line with the above findings, 
adenovirus mediated overexpression of IRF9 in the liver attenuated these 
phenotypes found in both genetically (ob/ob) and HFD-induced obese mice. At 
the molecular level, IRF9 was found to interact with  peroxisome proliferator-
activated receptor α (PPARα) and subsequently activate PPARα- target genes to 
regulate the metabolic process in the liver (Wang et al., 2013a). Other than IRF7 
and IRF9, IRF3 was shown to influence the development of metabolic disorder. 




hepatic steatosis. Adenovirus-mediated overexpression of IRF3 in the liver 
attenuated the systemic and hepatic inflammation observed in the IRF3 KO mice. 
Such phenotype was the result of increased NF-κB activation found in the liver of 
IRF3 KO mice upon HFD feeding (Wang et al., 2013b). In addition, IRF3 
interacted with the kinase domain of IKKβ in the cytoplasm and regulated its 
downstream signalling. Thus, IRF3 protects mice from HFD-induced hepatic 
insulin resistance and steatosis by interacting with IKKβ in the cytoplasm to 


















3.2 Objectives of the study 
Previous studies have demonstrated the expression of IRF3 was increased at the 
later stage of adipogenesis in 3T3-L1 pre-adipocytes. Overexpression of IRF3 in 
3T3-L1 cells inhibited lipid accumulation and terminal differentiation gene 
expression (Eguchi et al., 2008). However, the mechanisms by which IRF3 
regulates adipocyte differentiation were not well understood. Using IRF3 KO 
mice, IRF3 was recently demonstrated to protect mice from HFD-induced hepatic 
insulin resistance and hepatic steatosis (Wang et al., 2013b). However, the 
function of IRF3 in regulating metabolic disorders like insulin resistance and 
obesity-associated inflammation remains to be elucidated. Therefore, the main 
objectives of this study are (1) to understand the functional role of IRF3 in 
regulating obesity and obesity-associated metabolic syndromes including insulin 
resistance; (2) to study the mechanisms by which IRF3 negatively regulates 
adipogenesis; (3) To explore the role of IRF3 in regulating adipose tissue 











3.3.1 IRF3 expression is associated with obesity in mouse and human 
3.3.1.1 IRF3 expression is increased in adipose tissue in response to HFD  
WAT is the primary site of energy storage and dysfunction of WAT is the 
primary defect in obesity and obesity-related metabolic diseases (Spiegelman and 
Flier, 2001).  To study the involvement of IRF3 in regulation of adipose tissue 
function and metabolic diseases, C57BL/6 mice were given a HFD or normal 
chow diet for 8 weeks after weaning to examine the expression of IRF3 in various 
metabolic tissues including skeletal muscles, WAT and the livers. We detected 
significantly increased mRNA expression of IRF3 in WAT of mice fed with HFD 
compared with those under normal chow diet. In contrast, decreased expression of 
IRF3 was detected in the liver of diet-induced obese mice compared with their 
lean control. However, there was no significant difference on the expression of 
IRF3 in the skeletal muscles from lean mice and diet-induced obese mice. Among 
the three types of tissues, the expression of IRF3 was much higher in adipose 
tissue and the livers than that in skeletal muscles (Figure 3.3.1A). Western blot 
analysis showed that there was increased activation of IRF3 in the adipose tissue 
of diet-induced obese mice compared with that from mice given normal chow 
(Figure 3.3.1B). Additionally, a decrease in phosphorylation of IRF3 was also 
detected in the livers from HFD-fed mice compared with that from normal chow-
fed mice (Figure 3.3.1C). These evidence indicate the possible involvement of 







Figure 3.3.1 IRF3 expression is increased in WAT but decreased in the livers 
from HFD-induced obese mice compared to their lean controls. WT mice 
were fed normal chow (NC) or high fat diet (HFD) for 8 weeks after weaning. (A) 
IRF3 mRNA levels were detected in skeletal muscles, white adipose tissues 
(WATs) and the livers by QRT-PCR. Protein expression and phosphorylation of 
IRF3 in the WAT (B) and the liver (C) were detected by western blotting. β-actin 
is a loading control. All values are shown as the mean ± S.E.. The statistical 




3.3.1.2 Association of IRF3 expression with human obesity 
In addition to the correlation between the expression of IRF3 in adipose 
tissue and obesity in mouse, it is interesting to find that the expression of IRF3 in 
human obese subjects was correlated with insulin sensitivity measured using 
euglycemic clamp (Figure 3.3.2A). The expression of IRF3 in human was 
negatively associated with glycated hemoglobin, which is an indicator of 
glycemic control and a clinical marker of diabetes in subcutaneous adipose tissue 
(Furusyo and Hayashi, 2013) (Figure 3.3.2B). These evidence suggest the 
regulatory function of IRF3 in human obesity and diabetes. 
 
Figure 3.3.2  Increased IRF3 expression is associated with obesity in humans. 
(A) Association of IRF3 in subcutaneous tissue from human morbid obese subject 
with insulin sensitivity is determined by euglycemic clamp. (B) IRF3 expression 
in subcutaneous adipose tissue is negatively associated with glycated 
haemoglobin. NGT: non-glucose tolerance; IGT/IFG: Glucose/insulin tolerance; 




3.3.2 Development of obesity in IRF3 KO mice 
To study the role of IRF3 in obesity, we compared WT and IRF3 KO mice 
over a period of up to nine months (Figure 3.3.3A). The body weights of IRF3 
KO male mice were significantly higher than WT mice from the age of 4 months 
onwards. On the other hand, the body weights of IRF3 female KO mice were 
significantly higher than WT control mice from 6 months old (Figure 3.3.3A). 
The increased weight gain in IRF3 KO mice was manifested by increased 
accumulation of both visceral and subcutaneous fat, as we observed that IRF3 KO 
male mice at 5 months of age  and female mice at 6 months of age had larger 
perigonadal fat pads (also known as epididymal fat pads) and subcutaneous fat 
pads compared to WT mice (Figure 3.3.3C). We refer the perigonadal fat tissue as 
visceral WAT, as it is considered as “pure” white adipose tissue and is the major 
component of visceral adipose tissue (Bachmanov et al., 2001; Loncar et al., 
1988). Quantification of the weight of WAT showed that IRF3 KO mice had 
significantly heavier weight of both perigonadal fat pads and subcutaneous fat 
than WT control. Similar results were observed in female mice (Figure 3.3.3B). 
Together, these results demonstrated that deficiency of IRF3 resulted in the 





Figure 3.3.3 Mice deficient in IRF3 develop obesity. (A) Growth curve of WT 




perigonadal fat and subcutaneous fat from WT and IRF3 KO mice. (C) 
Representative pictures of isolated perigonadal fat and subcutaneous fat from WT 
and IRF3 KO mice. Male mice were at the age of 5 months old and female mice 
were at the age of 6months old in (B) and (C). All values are shown as the mean ± 
S.E.. The statistical significance is relative to the WT group, *p<0.05, **p<0.01. 
 
As shown in figure 3.3.3, IRF3 KO mice have increased body weight which 
is associated with increased weight of adipose tissues. To further characterize the 
adipose tissues, histological examination was performed to check the adipocytes 
in both perigonadal and subcutaneous fat. In line with increased body weight, 
hematoxylin and eosin (H&E) staining of WAT cross-sections revealed that the 
sizes of adipocytes in both perigonadal and subcutaneous fat from IRF3 KO mice 
were significantly larger than those in WAT from WT mice (Figure 3.3.4A). 
Quantification of these adipocytes showed that IRF3 KO mice had significantly 
increased size of adipocytes in both perigonadal and subcutaneous fat compared 
with their WT controls (Figure 3.3.4B). This suggests that there is more lipid 
accumulation in WAT of IRF3 KO mice, which contributes to the development of 







Figure 3.3.4 Increased size of adipocytes in WAT from IRF3 KO mice. (A) 
Representative micrographs of perigonadal and subcutaneous fat stained with 
H&E from WT and IRF3 KO mice at the age of 4 months old. (B) Bar charts 
showing adipocyte size in the cross-section of perigondal and subcutaneous fat 
from WT and IRF3 KO mice at the age of 4 months old. The statistical 
significance is relative to the WT group, **p<0.01. 
 
3.3.3 Reduced energy expenditure and physical activity in IRF3 KO mice 
Obesity results from a positive energy balance leading to accumulation of 
WAT (Christodoulides et al., 2009; Park et al., 2008).To address the possible role 




IRF3 KO mice, we analyzed the metabolic rate of WT and IRF3 KO mice using 
the Comprehensive Lab Animal Monitoring System (CLAMS). As shown in 
figure 3.3.5, 6 month old IRF3 male KO mice exhibited similar food intake 
compared with age-matched WT mice. However, IRF3 KO mice had significantly 
reduced energy expenditure associated with reduced respiratory rate (VO2) and 
respiratory quotient (RQ) (Figure 3.3.5).  Additionally, the activity of IRF3 KO 
mice was significantly lower than their WT controls. Together, these results 
suggest that deficiency of IRF3 in mice results in a positive energy balance which  
may lead to the development of obesity in IRF3 KO mice.    
 
Figure 3.3.5 IRF3 KO mice exhibit reduced energy expenditure and physical 
activity. Food intake, energy expenditure, activity, oxygen consumption and 
respiratory exchange ratio of WT and IRF3 KO mice at the age of 6 months were 
analyzed. All values are shown as the mean ± S.E..The statistical significance is 




3.3.4 Deficiency of IRF3 results in impaired insulin sensitivity and glucose 
homeostasis  
Obesity is associated with the development of insulin resistance and glucose 
intolerance (Bastard et al., 2006). In our study, insulin tolerance test (ITT) and 
glucose tolerance test (GTT) were employed to investigate the role of IRF3 in 
regulating insulin sensitivity and glucose homeostasis. Results showed that both 
IRF3 KO mice developed insulin resistance and glucose intolerance around the 
age of 5 months compared with WT mice (Figure 3.3.6A and 3.3.6B). In line with 
the impaired insulin sensitivity and glucose homeostasis, we detected significantly 
increased fasting blood glucose levels and fasting insulin levels in IRF3 KO mice 
at the age of 4 months (Figure 3.3.6C and 3.3.6D). Around the age of 8 months, 
IRF3 KO mice had significantly increased fasting glucose level which was around 
180mg/dL as well as significantly increased fasting serum insulin levels as 
compared with WT mice (Figure 3.3.6C and 3.3.6D), indicating that IRF3 KO 
mice developed hyperglycemia and hyperinsulinemia. In insulin signaling 
pathway, AKT is an important components. The activity of AKT reflects insulin 
sensitivity. Consistently, we decreased AKT activity in perigonadal fat, 
subcutaneous fat and skeletal muscles isolated from IRF3 KO mice compared 
with those of WT mice (Figure 3.3.6E). These evidences demonstrated that IRF3 
deficiency resulted in impaired glucose homeostasis and insulin sensitivity, which 





Figure 3.3.6 IRF3 deficiency results in impaired insulin sensitivity and 




WT and IRF3 KO mice during insulin tolerance test. (B) Line graph showing 
fasting blood glucose level in WT and IRF3 KO druing glucose tolerance test.  (C) 
Fasting blood glucose levels and (D) fasting blood insulin levels were determined 
on 4 and 8 month old mice. (E-F) Protein expression and phosphorylation of AKT 
in WAT (E) and skeletal muscle (F) were detected by western blotting. All values 
are shown as the mean ± S.E.. The statistical significance is relative to the WT 
group, p 0.05, p 0.01. 
 
3.3.5 IRF3 negatively regulates transcriptional network of adipogenesis 
3.3.5.1 IRF3 expression and phosphorylation is induced during adipogenesis 
Adipocytes have a central role in the pathogenesis of obesity and obesity-
related metabolic disorders such as insulin resistance (Guilherme et al., 2008). 
The expansion of WAT mass during the development of obesity is mediated 
through an increase in both adipocyte size and numbers. Previous study has 
showed that IRFs were transcriptional regulators of adipogenesis (Eguchi et al., 
2008). Therefore, in order to understand the role of IRF3 in adipogenesis, 
preadipocytes isolated from mouse adipose tissue and 3T3-L1 preadipocytes were 
performed in vitro adipocyte differentiation. Firstly, the expression and activation 
of IRF3 in WT pre-adipocytes isolated from both subcutaneous and pre-gonadal 
WAT were examined during adipogenesis. As shown in Figure 3.3.7A, both IRF3 
protein expression and activation were induced on Day5 after differentiation and 
were greatly increased on Day7 and Day9 in adipocytes isolated from both 
perigondal and subcutaneous fat. On the other hand,  during 3T3-L1 pre-
adipocyte differentiation, the expression and phosphorylation of IRF3 were 






level after Day6 (Figure 3.3.7B). These evidence indicate an important role of 
IRF3 in regulating adipocyte differentiation. 
 
 
Figure 3.3.7 IRF3 expression and activation is induced during adipogenesis. 
(A) Representative western blot analysis showing levels of total and 
phosphorylated IRF3 in cells isolated from perigonadal and subcutaneous fat 
during adipogenesis. (B) Representative western blot analysis showing levels of 
total and phosphorylated IRF3 in 3T3-L1 predipocytes during adipogenesis. β-





3.3.5.2 IRF3 negatively regulates adipogenesis 
To further examine the function of IRF3 in regulation of adipogenesis,      
pre-adipocytes were isolated from both WT and IRF3 KO WAT for in vitro 
adipocyte differentiation. The expression of genes associated with adipogenesis 
and their regulators in the WT and IRF3 KO cells during adipocyte differentiation 
was examined by QRT-PCR. As shown in figure 3.3.8A, the expression of PPARγ 
and C/EBPα, the two master regulators of adipogenesis, was significantly higher 
in IRF3 KO cells compared with WT cells during differentiation starting from 
Day5 to Day9. Consequently, the expression of lipogenic genes including the 
adipose-tissue specific fatty acid binding protein aP2/FABP4, acetyl-CoA 
carboxylase 1 (ACC1), fatty acid synthase (FAS), Stearoyl-CoA desaturase-
1(SCD1)  and lipid droplet binding protein perilipin 1 (Plin1) was significantly 
increased in IRF3 KO cells during differentiation compared with WT cells 
(Figure 3.3.8B). This suggests that IRF3 negatively regulates expression of 
adipogenic genes and their two master regulators PPARγ and C/EBPα. 
Interestingly, the expression of C/EBPβ and C/EBPδ, two transcriptional factors 
that facilitate the induction of PPARγ in adipocyte differentiation (Zuo et al., 
2006), was not changed by the deficiency of IRF3 (Figure 3.3.8A). This indicated 
that IRF3 might possibly regulate PPARγ and C/EBPα directly or through 








Figure 3.3.8 Deficiency of IRF3 lead to increased adipogenic gene expression. 
mRNA expression of important regulators of adipogenesis (A) and adipogenesis-
related genes (B) was examined in WT and IRF3 KO cells after differentiation 
from pre-adipocytes by quantitative QRT-PCR. All values are shown as the mean 
± S.E..The statistical significance is relative to the WT group, *p<0.05. 
 
 
Consistent with increased mRNA expression of PPARγ and C/EBPα in IRF3 
KO cells, western blots showed greatly increased protein expression of PPARγ 
and C/EBPα in IRF3 KO cells during differentiation starting from Day5 to Day11 
during differentiation compared with WT cells (Figure 3.3.9). This indicated that 
deficiency of IRF3 results in increased adipogenesis. In line with the increased 
ability of differentiation of IRF3 KO preadipocytes, IRF3 deficiency led to 
increased insulin sensitivity as evidenced by increased AKT activation in the 
IRF3 KO cells compared with WT cells during adipogenesis (Figure 3.3.9). To 
explore the effect of IRF3 deficiency on cell proliferation, ERK activation was 
examined in WT and IRF3 KO cells during adipocyte differentiation. As shown in 
figure 3.3.9, deficiency of IRF3 did not influence the level of ERK activation 
during adipocyte differentiation. This suggested that IRF3 was not required for 





Figure 3.3.9 Effect of IRF3 deficiency on genes involved in adipogenesis. The 
expression of PPARγ, C/EBPα, ERK phosphorylation and AKT phosphorylation 
was determined by western blots using lysate from WT and IRF3 KO cells during 
differentiation. β-actin is a loading control. 
 
In line with increased adipogenic gene expression in IRF3 KO adipocyte 
during differentiation, increased numbers of cells with lipid droplets accumulation 
was observed in IRF3 KO samples compared with WT controls on day 11 after 
differentiation (Figure 3.3.10A). Consistent with comparable ERK activation 
between WT and IRF3 KO cells (Figure 3.3.9), comparable cell numbers of WT 
and KO cells were detected on day 11 after differentiation (Figure 3.3.10B), 
indicating that IRF3 is not required for cell proliferation in adipogenesis.  
Taken together, deficiency of IRF3 promotes adipogenesis, which is 




downstream targeting adipogenesis-related genes. Deficiency of IRF3 also 
increased the numbers of lipid droplets in differentiated adipocytes. As such, IRF3 
is an important negative regulator of adipogenesis. 
 
Figure 3.3.10 Deficiency of IRF3 results in increased lipid droplets formation 
during adipogenesis. (A) micrographs showing the staining of lipid in WT and 
IRF3 KO adipocytes by Bodipy 493/503 after differentiation. (B) Total cell 
number was calculated in the figures using image J software. All values are 
shown as the mean ± S.E.. The statistical significance is relative to the WT group. 
3.3.6 IRF3 negatively regulates transcriptional network in adipocyte 
differentiation 
To further understand the role of IRF3 in transcriptional regulation in 
adipogenesis, gene expression microarray analysis of WT and IRF3 KO 




figure 3.3.11, sequential up-regulation of adipogenesis-related genes from Day3 
toward Day9 was observed in WT cells. A similar trend of adipogenesis-related 
gene upregulation was observed in IRF3 KO cells (Figure 3.3.11). However, 
compared with WT cells, IRF3 KO cells showed early upregulation of 
adipogenesis-related genes, especially on Day3 and Day5 after the initiation of 
differentiation. This was consistent with our observation that there was 
significantly increased expression of PPARγ and C/EBPα and their downstream 
targeting adipogenesis- related genes starting from Day3 of adipocyte 
differentiation (Figure 3.3.8 and 3.3.9).  
 
Figure 3.3.11 IRF3 negatively regulates transcriptional network in adipocyte 
differentiation. Heat map showing gene expression profile of adipocytes from 





As PPAR pathway is at the center of adipogenesis, we further analyzed the 
expression of PPAR-targeting genes. As shown in figure 3.3.12A, sequential up-
regulation of the expression of PPAR-targeting genes including C/EBP and 
adipoq was observed in both WT and IRF3 KO cells from Day3 to Day9 post 
differentiation. Most of these PPAR-targeting genes in IRF3 KO cells exhibited 
earlier and increased expression compared with these in WT cells at all time 
points examined (Figure 3.3.12A). Microarray data was confirmed by QRT-PCR 
using samples from WT and IRF3 KO cells after adipocyte differenetiation. 
Consistently, there was earlier and increased expression of important PPAR-
targeting genes in IRF3 KO cells during adipocyte differentiation compared with 
WT cells (Figure 3.3.12B). In addition, we cloned the promoter region of PPARγ 
into pGL3-basic vector and co-transfected this construct with IRF3 cDNA 
(pCDNA-IRF3) or control vector (pCDNA3.1) into NIH 3T3 cells. Luciferase 
activities were determined with or without PPARγ agonist rosiglitazone 
stimulation. We found that overexpression of IRF3 inhibited PPARγ promoter 
activity (Figure 3.3.12C). These results suggested that expression of PPARγ was 
negatively regulated by IRF3. Collectively, these results demonstrated a negative 










Figure 3.3.12 IRF3 negatively regulates PPARγ pathway. (A) Gene expression 
profile of WT an IRF3 KO pre-adipocytes during adipogenesis were examined by 
microarray analysis. Heat map showing PPARγ-targeting genes in WT and KO 
cells during differentiation (B) The expression of PPARγ-targeting genes in WT 
and IRF3 KO cells at various days indicated post differentiation was determined 
by QRT-PCR. (C) Luciferase activities were determined in the NIH 3T3 cells 
which were co-transfected with construct containing PPARγ promoter and 
pcDNA-IRF3 cDNA or pcDNA vector in response to rosiglitazone. All values are 
shown as the mean ± S.E.. *p<0.05. 
 
3.3.7 IRF3 deficiency results in increased macrophage infiltration and 
inflammation in WAT  
Inflammation is a key feature of obesity and obesity-associated disorders 
such as type 2 diabetes. Inflammatory macrophages which are recruited into WAT 
are primarily responsible for the inflammatory response in obesity (Chawla et al., 
2011; Hotamisligil, 2006). In our study, we observed significantly increased cell 
infiltration in both perigonadal fat and subcutaneous fat from IRF3 KO mice 
compared with those from WT mice (Figure 3.3.13A). In addition, the percentage 




 macrophages,  which are the inflammatory 




cells from WAT of IRF3 KO mice compared with those from WT mice (Figure 
3.3.13B). Sections of perigonadal WAT stained with anti-F4/80 antibody showed 
increased F4/80 positive cells surrounding adipocytes forming the typical crown-
like structure (CLS) in IRF3 KO WAT (Figure 3.3.13C). Thus, deficiency of 
IRF3 led to increased macrophage infiltration into WAT as well as increased 





Figure 3.3.13 Increased macrophage infiltration in IRF3 KO WAT. (A) Total 
infiltrated cell numbers in SVF isolated from both perigonadal (left panel) and 
subcutaneous fat (right panel) of WT and IRF3 KO mice at the age of 5 months. 
(B) SVF cells isolated from WT and IRF3 KO WATs were stained with 
antibodies against CD45.2, F4/80 and CD11c and analyzed by flow cytomentry. 
(C) F4/80 staining of sections of perigonadal fat from WT and IRF3 KO mice at 
the age of 4 months old. Scale bar denotes 100m. All values are shown as the 
mean ± S.E.. The statistical significance is relative too WT group. *p<0.05, 
**p<0.01. 
 
Obesity and insulin resistance are associated with a low grade inflammation 
in adipose tissue (Bastard et al., 2006). Therefore, we examined the expression of 
pro-inflammatory mediator in the WAT of both WT and IRF3 KO mice. There 
was significantly increased expression of inflammatory genes including Tnf, Il-6 
and Nos2 in IRF3 KO WAT (Figure 3.3.14A), indicating increased inflammation 
in the adipose tissue caused by IRF3 deficiency. Classically activated or M1 
ATMs highly express inflammatory cytokines including TNFα and iNOS, as well 
as promoting insulin resistance. On the other hand, alternatively activated or M2 
macrophages expressing genes such as macrophage galacotose N-acetyl-
galactosamine-specific lectin 1 and 2 (Mgl1 and Mgl2) and arginase I (Arg1) are 
protective against the development of insulin resistance (Kang et al., 2008; 
Lumeng et al., 2007). Therefore, we further characterized the phenotypes of WT 
and IRF3 KO ATMs by examining the expression of M1 and M2 macrophage 
markers genes in SVF isolated from WT and IRF3 KO mice. Consistent with 
increased M1-like macrophage population, there was increased expression of M1 




isolated from adipose tissue of IRF3 KO mice as compared with those from WT 
controls (Figure 3.3.14B). These evidence indicate that deficiency of IRF3 
promotes M1 macrophage activation and inflammation in adipose tissue. 
Interestingly, the expression of some M2 macrophage marker genes including 
Mrc2 and Chi3l3 was also increased in SVF from IRF3 KO mice (Figure 3.3.14B).  
Although there was increased expression of Mrc2 and Chi3l3 in SVF of IRF3 KO 
mice, decreased expression of Arg1 was detected in SVF of WAT from IRF3 KO 
mice compared with those from WT mice. Therefore, the function of IRF3 in M2 









Figure 3.3.14 Deficiency of IRF3 results in increased inflammation in adipose 
tissue. (A) mRNA levels of pro-inflammatory mediators TNFα, IL-6 and Nos2 
was determined in adipose tissue of WT and IRF3 KO mice by QRT-PCR. (B) 
mRNA levels of M1 macrophage marker genes (upper panel) and M2 
macrophage marker genes (lower panel) were determined in SVFs isolated from 
WAT of WT and IRF3 KO male mice at the age of 6 months old by QRT-PCR. 
All values are shown as the mean ± S.E.. The statistical significance is relative to 






To further understand the regulation of IRF3 in macrophage activation, WT 
and IRF3 KO BMDMs were subjected to M1 and M2 macrophage activation 
condition treatment. In response to M1 activation, the expression of M1 markers 
genes including Tnfa, IL-6, Nos2, IL12p35 and IL12p40 was increased in IRF3 
KO BMDMs compared with WT BMDMs (Figure 3.3.15A). Furthermore, there 
was more TNF and IL-6 production in the supernatant of IRF3 KO BMDMs 
compared with those of WT cells upon M1 activation (Figure 3.3.15C). These 
results demonstrated that deficiency of IRF3 results in increased M1 macrophage 
activation in BMDMs in response to M1 inducer. Upon stimulation with IL-13 
(M2 inducer), there was also increased expression of M2 macrophage marker 
genes including Mgl1, Mgl2, Arg, Mrc2, Chi3l3 in IRF3 KO BMDMs. In fact, the 
expression of IL-10 was reduced in IRF3 KO BMDMs in response M2 activation 






Figure 3.3.15 Deficiency of IRF3 results in increased M1 macrophage 




expression of M1 (A) or M2 (B) macrophage marker genes was examined by 
QRT- PCR respectively. (C) IL-6 and TNFα concentration was detected in culture 
supernatant of BMDMs in response to M1 activation condition. All values are 
shown as the mean ± S.E.. The statistical significance is relative to the WT group, 
*p<0.05.  
3.3.8 IRF3 KO mice develop hepatic steatosis at a later stage of life 
Hepatic steatosis is an important manifestation of metabolic dysfunction. To 
examine the effect of IRF3 deficiency on the liver, we examined the livers from 
WT and IRF3 KO mice at the ages of 4 and 9 months old. The livers from young, 
4 months old IRF3 KO mice and WT mice were similar in size and weight 
(Figure 3.3.16A). However, in aged mice, we found that the livers of IRF3 KO 
mice were larger and paler than those from WT mice (Figure 3.3.16A). 
Quantification of the liver weight showed that IRF3 KO mice displayed 
significantly increased liver weight compared to WT controls (Figure 3.3.16B). 
H&E staining of the cross-sections of the liver samples showed that IRF3 KO 
mice developed hepatic steatosis at the age of 9 months old. Oil Red O staining 
confirmed increased lipid content and larger lipid droplets accumulation in the 
livers of IRF3 KO mice (Figure 3.3.16C). In addition, triglyceride levels and 
NEFA levels in the livers of IRF3 KO mice were increased (Figure 3.3.16D). 
However, there was comparable serum triglyceride and serum NRFA levels 
between WT and IRF3 KO mice (not shown). The evidence suggests deficiency 
of IRF3 also lead to impaired lipid metabolism in the liver. Taken together, IRF3 





Figure 3.3.16 IRF3 KO mice develop hepatic steatosis a later stage of life. (A) 





months. (B) Body weight and liver weight of WT and IRF3 KO mice. (C) 
Representative sections of liver stained with H&E (upper panel) and Oil red O 
(lower panel) from WT and IRF3 KO mice at the age of 9 months. (D) The levels 
of hepatic triglyceride (TG) and hepatic non-esterified fatty acid (NEFA) 
extracted from the livers of WT and IRF3 KO mice at the age of 9 months. Scale 
bar denotes 100μm. Data are shown as mean  S.E.. The statistical significance is 
relative to the WT group, p 0.05, p 0.01. 
 
The molecular mechanisms involved in the accumulation of TGs in the liver 
are very complicated. Fatty acid from lipogenic pathway is one of the major 
sources for excessive TG formation and storage in the liver (Cohen et al., 2011). 
To further understand the function of IRF3 in hepatic lipid metabolism, we 
compared the lipogenic gene expression in livers from WT and IRF3 KO mice. 
We found that expression of lipogenic genes including ACC1 and FAS was 
increased in the liver of IRF3 KO mice compared to WT controls (Figure 3.3.17). 
In addition, increased expression of the master regulators of lipogenesis including 
SREBP1c and PPARγ was detected in the livers of IRF3 KO mice. Beside, 
slightly decreased expression of fatty acid oxidation genes including VLCAD and 
MCAD in the liver from IRF3 KO mice compared with those from WT controls 
was detected. Together, these results suggest that the increased lipid accumulation 





Figure 3.3.17 IRF3 KO mice have increased lipogenic gene expression in the 
liver.  mRNA expression of lipogenic genes in the livers of WT and IRF3 KO 
mice were examined by QRT-PCR. All values are shown as the mean ± S.E.. The 







As important transcription factors, IRFs are implicated in the regulation of 
many immune processes such as anti-viral immunity (Honda and Taniguchi, 
2006). Recently, IRFs including IRF4, IRF7 and IRF9 have been demonstrated to 
regulate metabolism (Eguchi et al., 2013; Eguchi et al., 2011; Wang et al., 2013a; 
Wang et al., 2013c). In our study, we showed that IRF3 was an important 
regulator of adipogenesis and its expression was protective for obesity and 
obesity-related metabolic complications including insulin resistance, type 2 
diabetes and hepatic steatosis. First, we found that IRF3 KO mice displayed obese 
phenotype with reduced energy expenditure. As obesity is associated with other 
metabolic disorderss such as insulin resistance, the role of IRF3 in regulating 
insulin sensitivity and glucose homeostasis was subsequently investigated. Mice 
deficient in IRF3 exhibited impaired insulin sensitivity and developed glucose 
intolerance as well as type 2 diabetes at later stage of life, indicating the important 
function of IRF3 in regulating insulin sensitivity and glucose homeostasis. IRF3 
KO mice also developed hepatic steatosis at the age of 9 months old, which was 
consistent with Wang’s observation that deficiency of IRF3 promoted HFD-
induced hepatic steatosis (Wang et al., 2013b). Together, IRF3 has emerged as an 
important regulator in metabolism and it protects mice from the development of 






3.4.1 Different expression and activation pattern of IRF3 in metabolic tissues 
in response to over-nutrition 
IRF3 is expressed constitutively in a variety of tissues and cells (Lin et al., 
1999b). In this study, we found that over-nutrition resulted in different expression 
and activation pattern of IRF3 in metabolic tissues and organs including adipose 
tissue, skeletal muscles and the livers. Upon HFD feeding, WT mice had 
significantly increased expression and activation of IRF3 in WAT compared with 
their lean controls, suggesting IRF3 may be involved in regulating metabolic 
processes in adipose tissue (Figure 3.3.1A and 3.3.1B). In contrast, we observed 
decreased expression and activation of IRF3 in the liver of HFD-induced obese 
mice (Figure 3.3.1A and 3.3.1C). Previously, Wang et al. reported that IRF3 
expression in the liver was decreased in mice with diet-induced and genetic 
obesity (Wang et al., 2013b). This was consistent with our finding that HFD 
feeding led to decreased expression and activation of IRF3 in the liver. However, 
we did not detect significant difference in expression of IRF3 in the skeletal 
muscles of diet-induced obese mice and their lean controls (Figure 3.3.1A). The 
different expression and activation pattern of IRF3 in various metabolic tissue 
responding to overnutrition may be explained by different function of IRF3 and 
the distinct metabolic processes mainly occurred in these metabolic tissues. For 
instance, the main function of adipose tissue is to store excess lipids in the form of 
TG whereas the skeletal muscles utilize glucose to produce energy for body 
movement (Vernon et al., 1987). However, the cause of the up-regulation of IRF3 




IRF3 in liver during obesity development remains to be elucidated. To address 
this question, tissue-specific IRF3 KO mice could be utilized to understand the 
regulatory mechanism of IRF3 in different metabolic tissues. 
3.4.2 Important roles of IRF3 in metabolism  
In this study, we examined the function of IRF3 in regulating obesity and 
obesity-associated metabolic disorders using the IRF3 KO mouse model. Mice 
deficient in IRF3 displayed obesity with increased adiposity in adipose tissue 
(Figure3.3.3 and 3.3.4). Obesity is largely due to an imbalance between energy 
intake and energy expenditure (Park et al., 2008). Using the comprehensive Lab 
Animal Monitoring System (CLAM), IRF3 KO mice were found to have 
significantly reduced energy expenditure associated with reduced respiratory rate 
and respiratory quotient as well as reduced physical activity (Figure3.3.5), which 
resulted in a positive energy balance to contribute to the development of obesity. 
In rodents, thermogenesis in brown adipose tissue might account for more than 50% 
of the total body metabolic activity (Saito, 2013). Additionally, obesity is often 
associated with reduced thermogenic activity (Lin and Li, 2004). Therefore, 
future work should also focus on elucidating the role of IRF3 in brown adipose 
tissue (BAT).  First, histological examination should be performed to characterize 
WT and IRF3 BAT. Second, genes related to thermogenesis and fatty acid 
oxidation can be detected in WT and IRF3 KO BAT. Next, cold tolerance test will 
be performed on WT and IRF3 KO mice to study the function of IRF3 in 




specific knockout mice can be utilized to elucidate the effect of IRF3 deficiency 
in BAT on obesity and obesity- associated metabolic conditions. 
3.4.3 IRF3 acts as a novel regulator for PPARγ during adipogenesis 
The formation of adipocytes from pre-adipocytes (adipocyte differentiation or 
adipogenesis) and the size increase of adipocytes due to fat storage (adipocyte 
hypertrophy) are the two key processes in determination of fat mass (Jo et al., 
2009). As a dominant and essential regulator, PPARγ transcriptionally controls 
pre-adipocyte differentiation into mature adipocytes and the accumulation of 
lipids in the adipocytes (Lefterova et al., 2008). However, little has been known 
about the regulation of PPARγ in adipocyte differentiation. For the first time, we 
showed that IRF3 negatively regulates PPARγ and PPARγ-targeting genes in 
adipocytes, thus preventing hypertrophic obesity. In particular, the deficiency of 
IRF3 promotes adipogenesis by upregulating PPARγ and PPARγ-dependent 
adipogenic gene expression (Figure3.3.8, 3.3.9 and 3.3.12). This indicated a 
possible regulation of PPARγ by IRF3. Furthermore, the luciferase assay 
confirmed that IRF3 negatively regulated the expression of PPARγ 
(Figure3.3.12C). However, the question of whether PPARγ can be directly 
regulated by IRF3 remains to be addressed.  If IRF3 directly regulates PPARγ by 
binding to its promoter region, the bindings of IRF3 in PPARγ promoter region 
will be identified by ChIP assay using IRF3 antibody.  
In addition, it is interesting to observe the induction of both IRF3 expression 




an important role of IRF3 in regulating adipocyte differentiation from pre-
adipocytes. As a transcription factor, IRF3 needs to be phosphorylated and 
translocated into nucleus to regulate gene expression. Currently, it is not clear on 
how the expression and activation of IRF3 occurs during adipogenesis. Previous 
studies have shown that adipocyte proliferation and differentiation were regulated 
by secreted growth factors (Yamasaki et al., 1999). At the same time, members of 
the fibroblast growth factor such as FGF1, FGF10 and FGF21 was shown to play 
important role in WAT development (Ohta and Itoh, 2014). In our microarray 
data, several FGFs expression was highly expressed in both WT and IRF3 KO 
adipocytes during differentiation. Thus, FGFs may be a possible source of 
stimulation which induce the expression and phosphorylation of IRF3 during 
adipogenesis. Thus, the 3T3-L1 differentiation in the presence of FGFs will be 
performed to examine the expression and activation of IRF3 during adipogenesis.  
3.4.4 Inflammation may contribute to insulin resistance in IRF3 KO mice 
Obesity-induced chronic inflammation is a key component in the 
pathogenesis of insulin resistance and the metabolic syndrome. The infiltrated 
macrophages in WAT are the major contributors to inflammation and insulin 
resistance (Olefsky and Glass, 2010).  Additionally, it has been shown that the 
recruitment of macrophages into WAT in obesity and the phenotypic switch of 
ATMs from alternative or anti-inflammatory activation to pro-inflammatory is 
important for the development of insulin resistance and related metabolic 




had increased adipose tissue inflammation, which was accompanied with 
increased inflammatory cytokine expression and macrophage infiltration into 
WAT. In addition, there was increased percentage and cell numbers of pro-
inflammatory M1 macrophages in SVF isolated from IRF3 KO mice WAT 
compared with that from WT mice (Figure 3.3.13). In line with this, increased 
expression of M1 macrophage marker genes was also detected in IRF3 KO SVF 
and BMDMs (Figure 3.3.14B). These data indicates that IRF3 suppresses the 
expression of inflammatory cytokine genes including IL-1β, TNFα and IL-6 
(Tarassishin et al., 2011). Furthermore, IRF3 itself is an inhibitor of macrophage 
M1 polarization and deficiency of IRF3 resulted in increased M1 activation. 
Besides, increased expression of two M2 macrophage markers including Mrc2 
and Chi3l3 was detected in SVF from IRF3 KO mice (Figure 3.3.14B). In contrast, 
significantly decreased expression of Arg1was also detected, which lead to the 
confusion on the function of IRF3 in regulating M2 macrophage activation. 
However, we still detected decreased percentage and cell numbers of M2 
macrophages and increased percentage and cell numbers of M1 macrophage in 
IRF3 KO SVFs compared with those in WT SVFs (Figure 3.3.13), indicating 
deficiency of IRF3 promotes the switch of ATMs from alternative or anti-
inflammatory activation to proinflammatory activation. Thus, IRF3 is a novel 
regulator for ATM polarization. However, the mechanism by which IRF3 
regulates macrophage activation remains to be known. IRF3 is an important 
transcription factor required for IFNβ expression. IFNβ was reported to regulate 




did detect decreased expression of IFNβ in IRF3 KO BMDMs in response to M1 
activator and FFA stimulation. In addition, IRF3 KO BMDMs also had decreased 
expression and secretion of IL10. Therefore, one of the possible mechanisms by 
which IRF3 regulates ATM polarization may be the suppression of anti-
inflammatory response due to deficiency of IRF3. To address this, we can 
stimulate WT and IRF3 KO BMDMs with combination of IL10 with M1 activator 
or FFA and then detect expression and secretion of pro-inflammatory genes such 
as IL6, TNFα and IL-1β. 
Our data demonstrated that IRF3 KO mice displayed obesity and developed 
insulin resistance which was associated with increased adipogenesis and increased 
macrophage infiltration and inflammation in WAT. These findings raised an 
important question on whether the development of insulin resistance and other 
metabolic disorders in IRF3 KO mice is primarily caused by a defect in the 
macrophages or adipocytes or both. To answer this question, we will perform co-
culture of adipocytes with WT or IRF3 KO BMDMs in vitro to investigate if 
IRF3 deficiency in macrophages could interfere insulin response in adipocytes 
during macrophage-adipocyte interaction. In addition, mixed bone marrow 
reconstitution experiment will be performed to generate mice lacking IRF3 in 
either hematopoietic cells or non-hematopoietic cells compartments to further 
understand the role of IRF3 in different cellular compartments in regulating 




3.4.5 IRF3 protects mice from the development of hepatic steatosis  
It was shown that IRF3 KO mice had increased hepatic inflammation and 
developed more severe hepatic steatosis compared with WT mice upon HFD 
feeding (Wang et al., 2013b). Increased NFB activation was detected in the liver 
from IRF3 KO mice in response to HFD. Overexpression of the inhibitor of κB-α 
(IκBα) specifically in the liver reversed the HFD-induced insulin resistance and 
steatosis in IRF3 KO mice (Wang et al., 2013b). These observations led to a 
conclusion that IRF3 inhibited NFB activation in the liver to alleviate hepatic 
inflammation, insulin resistance and hepatic steatosis. Here we found that IRF3 
KO mice developed hepatic steatosis under normal chow with age (Figure 3.3.16). 
Interestingly, under normal chow, we found that the activation of NFB was 
comparable between WT and KO mice in the livers despite IRF3 KO mice 
displayed hepatic steatosis. It has been shown that HFD-mediated obesity 
increased NFB activation in the liver (Cai et al., 2005).Thus, it is possible that 
the increased NFB activation in the liver of IRF3 KO mice reported in previous 
study is also a secondary response to HFD-mediated obesity and inflammation.   
Obesity increases risks of insulin resistance and hepatic steatosis. In our study, 
we found that IRF3 KO mice developed obesity and obesity-associated insulin 
resistance followed by hepatic steatosis. There is a question on whether hepatic 
steatosis in IRF3 KO mice is due to the direct effect of IRF3 deficiency in liver or 
a deficiency on effect of obesity and adipose tissue phenotype. To address this, 
adipose tissue- specific knockout or liver- specific knockout mice can be utilized 




IRF3 deficiency either in liver or WAT or both. Alternatively, mice with 
adenovirus- mediated overexpression/knockdown of IRF3 in the liver could also 
be beneficial to study the function of IRF3 in the development of hepatic steatosis. 
3.5 Conclusion 
In this study, we have systemically investigated roles of IRF3 in regulating 
inflammation and metabolism by using both in vivo and in vitro models. This 
study mainly consisted of three parts: (i) understanding the roles of IRF3 in 
obesity and obesity- associated metabolic conditions including insulin resistance 
and hepatic steatosis; (ii) investigation on the mechanism by which IRF3 
negatively regulates adipocyte differentiation; (iii) Examination on the role of 
IRF3 in regulating adipose tissue inflammation and contribution of inflammation 
to insulin resistance in IRF3 KO mice. The main findings are: 
       (1) IRF3 protects mice from obesity and obesity- associated metabolic 
conditions. 
           (i) IRF3 expression is asscoated with obesity in mouse and human 
           (ii) IRF3 KO mice develop obesity due to positive energy balance 
           (iii) Deficiency of IRF3 results in impaired insulin sensitivity and glucose 
homeostasis, and increase the risk of hepatic steatosis 
       (2) IRF3 negatively regulates adipogensis by targeting PPARγ IRF3 protects 
mice from obesity and obesity- associated metabolic conditions. 
           (i) IRF3 expression and activation is induced during adipogenesis 
           (ii) Deficiency of IRF3 results in increased expression of PPARγ and 




       (3) IRF3 acts as negative regulator for adipose tissue inflammatory activation.  
           (i) Deficiency of IRF3 results in increased adipose tissue inflammation 
which is accompanied with increased inflammatory macrophage infiltration and 
increased expression and secretion of inflammatory cytokines 
           (ii) Deficiency of IRF3 results in a switch of macrophage polarization from 
anti-inflammatory to proinflammatory status. 
 Taken together, we have demonstrated the crucial role of IRF3 in regulating 
inflammation and metabolism. We believe that data from this study will 
contribute to current literature for the function of IRF3, particular in control of 
metabolism, which provide a foundation for the development of novel therapeutic 

























CHAPTER 4  
REGULATORY ROLE OF MKP5 IN THE DEVELOPMENT 















The mitogen-activated protein kinase (MAPK) pathways are evolutionally 
conserved signalling pathways. MAPKs relay various extracellular stimuli to 
activate multiple downstream cellular programmes and regulate various 
physiological processes (Seger and Krebs, 1995). The activity of MAPKs needs to 
be tightly regulated since inappropriate MAPK signalling results in the 
development of various diseases including cancer and metabolic disorders. One 
key negative regulator for MAPKs is the MAPK phoshatases (MKPs), which is a 
family of proteins that dephosphorylate MAPKs at both threonine and tyrosine 
residues located in the activation loop of MAPKs (Haneda et al., 1999; Zhang and 
Dong, 2007a). The following sections provide an overview of MAPKs and 
regulation by MKPs with a focus on roles of MKPs in metabolism. 
4.1.1 Mitogen-activated protein kinases (MAPKs)  
MAPKs are important mediators that transduce extracellular signals such as 
inflammation and environmental stresses into cytoplasm and nucleus to generate 
an appropriate physiological response (Seger and Krebs, 1995). In mammals, 
there are three major groups of MAPKs including the p38 MAP kinases, the 
extracellular signal-regulated protein kinases (ERK), and the c-Jun NH2-terminal 
kinases (JNK). All these MAPKs consist of a Thr-X-Tyr (TXY) motif within their 
activation loop. Activation of MAPKs is achieved by the phosphorylation of both 
threonine and tyrosine (Cobb and Goldsmith, 1995). The p38 family has a TGY 




(Lechner et al., 1996). The ERK family contains a TEY (Thr-Glu-Tyr) activation 
motif and can be further divided into two subgroups: (1) the classic MAPKs such 
as ERK1 and ERK2 that consist primarily of a kinase domain and (2) the large 
MAPKs such as ERK3, ERK5, ERK7 and ERK8 that consist of both a kinase 
domain and a C-terminal domain (Kuo et al., 2004). The JNK family has three 
members, JNK1, JNK2 and JNK3 which contain Thr-Pro-Tyr (TPY) in their 
activation motif (Kyriakis et al., 1994).  
A core triple kinase cascade consisting of MAP3Ks-MAPKKs-MAPKs is 
required for MAPKs activation. As shown in figure 4.1.1, an extracellular stimuli 
activates GTPases of the Ras/Rho family and leads to signal transmission through 
MAPK-related protein kinase cascades. The MAP3Ks phosphorylate and activate 
MAPKKs. Subsequently, MAPKKs activate MAPKs by dual phosphorylation of 
tyrosine and threonine residues on the activation loop of MAPKs. Activated 
MAPKs can target a variety of substrates that regulates different cell processes 





Figure 4.1.1 Mammalian MAPK pathways. MAPKs are activated by dual 
phosphorylation of tyrosine and threonine residues through upstream triple kinase 
cascades  (Zhang and Dong, 2007b). 
4.1.2 MAPK phosphatases (MKPs) are negative regulators of MAPKs  
The activation of MAPKs including the magnitude and duration of their 
activation are critical in mediating appropriate physiological responses (Zhang 
and Dong, 2007b). Therefore, negative regulators of the MAPKs play critical 
roles in MAPK-mediated responses. In mammalian cells, the inactivation of 
MAPKs is achieved by a group of proteins collectively named MAPK 
phosphatases (MKPs) (Camps et al., 2000).  
MKPs or dual specificity phosphatases (DUSPs), are able to dephosphorylate 
MAPKs at both phosphothreonine and phosphotyrosine residues simultaneously 
within the Thr-X-Tyr located in the activation loop of MAPKs (Zhang and Dong, 





them being considered as typical MKPs. These typical MKPs normally have a 
structure consisting of a N-terminal noncatalytic domain and a conserved C-
terminal catalytic domain. The N-terminal domain has two regions of homology 
with the Cdc25 cell cycle regulatory phosphatase. Being more conserved than the 
N-terminal within MKPs, the catalytic domain contains a highly conserved 
signature motif, HCXXXXXR. Despite sharing the common structure, each MKP 
has different substrates specificities and distinct subcellular localizations. Based 
on substrate specificity and localization of MKPs, the family of MKPs can be 
further divided into three different subgroups (Figure 4.1.2) (Caunt and Keyse, 
2013).  The first group is inducible nuclear MKPs including MKP1/DUSP1, 
DUSP2, MKP2/DUSP4 and DUSP5. These MKPs have 4 exons and introns 
which may originate from a common ancestral gene. They were shown to 
dephosphorylate all MAPKs to the same extent. The second group was identified 
as cytoplasmic ERK-specific MKPs including MKP3/DUSP6, DUSP7 and 
MKP4/DUSP9. These MKPs specifically dephosphorylate ERK. The third group 
MKPs include DUSP8, MKP5/DUSP10 and MKP7/DUSP16, which 
preferentially inactivate p38 and JNK rather than ERK. Although each MKP 
targets different subsets of MAPKs, there is an overlap between their substrate 
specificities. This is probably due to gene duplication and gene divergence during 






Figure 4.1.2 Classification of MKPs (Caunt and Keyse, 2013). 
4.1.3 Regulation of MKPs  
The activities of MKPs also require proper regulation. Similar to the 
regulation of MAPKs, MKPs are subjected to the regulation at multiple levels 
including transcriptional and post-translational levels (Caunt and Keyse, 2013). 
First, many MKPs are inducible. They have low expression in resting, non-
stimulated cells and their expression are rapidly induced in response to 
appropriate stimulation. The induction of these MKPs is often dependent on the 
activation of MAPKs. Thus, MAPKs-MKPs are thought to be a negative-feedback 
mechanism for down-regulation of mitogenic signalling (Patterson et al., 2009). 
MKPs may also be regulated at the post-translational level. They can be 
phosphorylated directly by their substrate(s), which leads to increased 
stabilization and prolonged half-life of the MKPs (Brondello et al., 1999; Katagiri 




modification to limit their activity was also documented (Xu et al., 2005b). In 
addition, MKPs can be catalytically activated and inhibited. The enzymatic 
activity of MKPs is sensitive to reversible oxidation and inactivation owing to the 
presence of the catalytic cysteine residue in the catalytic domain (Kamata et al., 
2005). Reversible oxidation of the conserved cysteine within the DUSP catalytic 
domain abolishes its nucleophilic properties and leads to profound changes in the 
conformation of the catalytic cleft, rendering the phosphatase inactive (Kamata et 
al., 2005). These studies collectively indicate that multiple mechanisms are 
involved in the regulation of MKP expression, activity and stability. However, 
more studies are required to understand the intricate mechanism of the MKPs 
regulation. 
4.1.4 MKPs involved in regulation of metabolism 
In the past decade, several MKP members including MKP1, MKP3 and 
MKP4 were implicated in the regulation of metabolism. Using MKP1 KO mice, 
the function of MKP1 in metabolism has first been revealed (Flach et al., 2011; 
Wu et al., 2006). Mice deficient in MKP1 displayed lean phenotype with 
decreased adiposity and reduced energy expenditure. They were also resistant to 
HFD-induced insulin resistance and hepatic steatosis.  In skeletal muscles, ERK, 
JNK and p38 were all hyper-activated in MKP1 KO mice compared with WT 
mice, which led to increased mitochondrial respiration. In the liver, deficiency of 
MKP1 led to increased activation of both p38 and JNK but not ERK. This in turn 




development of HFD-induced hepatic steatosis (Wu et al., 2006). In addition to 
inhibiting fatty acid oxidation, MKP1 was also found to promote hepatic 
lipogenic gene expression through PPARγ and had a protective role in hepatic 
steatosis by suppressing Fsp27/Cidec (Flach et al., 2011). Thus, MKP1 regulates 
metabolism in different metabolic tissues with distinct mechanisms. 
On the other hand, MKP3 was identified as a novel regulator for 
gluconeogenesis by Xu and his colleagues (Xu et al., 2005a). They found that 
mice with overexpression of MKP3 in the liver displayed increased fasting blood 
glucose levels and insulin levels (Xu et al., 2005a). Knockdown of MKP3 in the 
liver of mice reduced the fasting blood glucose levels and improved insulin 
sensitivity. Mechanistically, MKP3 promoted hepatic glucose production and 
activated gluconeogenic gene expression through dephosphorylation of forkhead 
box O1 (Fox O1), indicating that MKP3 played an important role in modulating 
the hepatic gluconegenic program (Xu et al., 2005a). Recently, the function of 
MKP3 in metabolism was further investigated by using MKP3 KO mouse model. 
The MKP3 KO mice were resistant to the development of HFD-induced obesity 
due to reduced adiposity (Feng et al., 2014). Deficiency of MKP3 inhibited 
adipocyte differentiation and decreased lipid production and accumulation in the 
adipocytes. In addition to regulate the gluconeogenesis, MKP3 was found to 
regulate hepatic lipid metabolism by dephosphorylating HDAC1/2 (Feng et al., 
2014). These results collectively demonstrated that MKP3 plays important roles 




Recently, our group found Mice deficient in MKP5 displayed visceral obesity 
and develop insulin resistance spontaneously at early stage of life and glucose 
intolerance at a later stage. Mixed bone marrow experiments showed that 
deficiency of MKP5 in hematopoietic cells predominately contributes to insulin 
resistance. These data indicate an important role of MKP5 in regulating 
metabolism. 
4.1.5 Lipid droplet-associated proteins: Cell death-inducing DFF45-like 
effector (CIDE) proteins 
CIDE family consists of Cidea, Cideb and Cidec/Fat specific protein 27 
(Fsp27). They were first identified by their sequence homology with the N-
terminal domain of the DNA fragmentation factor (DFF) and were proved to be 
involved in caspase-dependent apoptosis (Inohara et al., 1998). Recent studies 
using gene knockout mice models have revealed their novel roles in regulating 
energy metabolism (Li et al, 2007; Zhou et al, 2003).  
4.1.5.1 CIDE proteins and their distribution 
CIDE proteins are evolutionarily conserved proteins. They contain an 
evolutionary conserved CIDE-N domain that shares homology to DFF40/45 
proteins and a CIDE-C domain that is unique among CIDE proteins (Inohara et al., 
1998). CIDE family proteins are known to have distinct tissue expression patterns. 
Cidea is predominately expressed in brown adipose tissue (BAT) in rodents, 
whereas Cideb is highly expressed in the liver and Fsp27/Cidec is mainly 




addition to understanding their tissue distribution, much effort has also been made 
to learn the sub-cellular localization of the CIDE proteins. Cidea and Cideb were 
found to co-localized with mitochondria when overexpressed in cells, suggesting 
the roles of these two proteins in apoptosis (Chen et al., 2000; Zhou et al., 2003). 
Interestingly, Cidea and Fsp27/Cidec were discovered to localize around the lipid 
droplets. Overexpression of Cidea or Fsp27/Cidec promotes lipid droplet growth 
and accumulation, indicating the importance of these two proteins in regulation of 
lipid droplet formation and lipid metabolism (Puri et al., 2007; Puri et al., 2008).  
4.1.5.2 The roles of CIDE proteins in metabolism 
Recent studies have shown that CIDE proteins play important roles in 
regulating energy metabolism. Mice deficient in CIDE proteins displayed a lean 
phenotype, resistance to HFD-induced obesity, insulin resistance and hepatic 
steatosis (Li et al., 2007; Matsusue et al., 2008; Zhou et al., 2003). In 2003, 
Professor Peng Li’s group generated Cidea KO mice to study the function of 
Cidea in metabolism. The Cidea KO mice exhibited a remarkable lean phenotype 
with higher metabolic rate and lipolysis in BAT and an increase in core body 
temperature compared with WT mice (Zhou et al., 2003). Mechanistically, it was 
found that Cidea regulated thermogenesis through its direct suppression of UCP1 
activity. Similarly, mice deficient in Cideb were resistant to HFD-induced obesity 
and hepatic steatosis, which was associated with decreased adipose tissue and 
increased metabolic rates as well as significantly lower levels of plasma FFAs and 




hepatic fatty acid oxidation and inhibiting lipogenesis (Li et al., 2007). Lastly, the 
lipid droplet-associated protein, Fsp27 that can promote the formation of 
unilocular lipid droplets was also shown to play a role in metabolism (Nishino et 
al., 2008). Mice deficient in Fsp27 displayed lean phenotype with a decreased 
WAT mass compared with WT controls. In addition, Fsp27 KO mice were less 
susceptible to diet-induced insulin resistance and hepatic steatosis (Matsusue et al., 
2008). Interestingly, expression of Fsp27/Cidec was markedly increased in both 
human and mouse with hepatic steatosis (Zhou et al., 2012). The above mentioned 
studies demonstreated the association of CIDE proteins in the regulation of 

















4.2 Objectives of the study 
MAPKs are important mediators that are activated by extracellular signals to 
stimuli. This in turn triggers intracellular signaling pathways that control various 
cellular responses including cell metabolic processes. As critical negative 
regulators of MAPKs, several MKPs including MKP1, MKP3 and MKP4 were 
implicated in regulating metabolism. Recently, our group found that MKP5 KO 
mice displayed obese phenotype and developed insulin resistance and glucose 
intolerance. Since insulin resistance increases the risk of other metabolic disorders 
such as hepatic steatosis, we hypothesize that MKP5 negatively regulates the 
development of hepatic steatosis. To address this, our study was focused on the 
following main aspects: (1) to investigate the effect of MKP5 deficiency on the 
development of hepatic steatosis (2) to study the mechanisms by which MKP5 
regulates the development of hepatic steatosis (3) To determine the the substrate(s) 
of MKP5 in the liver as MKPs are important negative regulators of MAPKs. In 
addition, the potential regulation of fatty liver disease development by MKP5 












4.3.1 MKP5 knockout mice develop hepatic steatosis upon NC feeding 
To investigate the role of MKP5 in the development of hepatic steatosis, we 
first compared MKP5 KO mice with age-matched WT mice upon normal chow 
feeding. As shown in figure 4.3.1B, there was no significant difference in body 
weight between WT and MKP5 KO mice at the age of 8 months old. However, 
MKP5 KO mice had significantly increased liver weight than WT mice. In 
addition, livers from MKP5 KO mice appeared to be more pale than those from 
WT mice (Figure 4.3.1A). To further characterize the livers from WT and MKP5 
KO mice, histological examinations including H&E staining and Oil- Red O 
staining were performed on WT and KO liver sections. As shown in figure 4.3.1C, 
there were obvious vacuoles present in the liver sections of MKP5 KO mice, 
indicating more lipid accumulation in the liver of MKP5 KO mice. Oil Red O 
staining confirmed markedly increased lipid accumulation in the liver section of 
MKP5 KO mice than that of WT controls. Upon measurement of TG contents in 
the livers of WT and MKP5 KO mice, significantly increased hepatic TG levels 
were detected in the liver of MKP5 KO mice compared with that of WT mice. 
Together, these evidence demonstrated that MKP5 KO mice are more susceptible 







Figure 4.3.1 MKP5 KO mice develop hepatic steatosis. (A) Representative 
images of livers from WT and MKP5 KO mice. (B) Bar charts showing body 
weight and liver weight of mice. (C) Representative micrographs showing H&E 
and Oil Red O staining in liver tissues. Scale bar denotes 100μm. (D) Bar charts 
showing hepatic triglycerides levels of mice. (E) MKP5 expression in WT and 
MKP5 KO livers. All values are shown as the mean ± S.E.. The statistical 
significance is relative to WT group.  *p< 0.05. 
4.3.2 Effects of HFD on expression of MKP5 and activation of MAPKs 
HFD can accelerate the development of obesity and its associated metabolic 
syndromes. HFD-induced obese rodent models are widely used in metabolic 
research. To facilitate the study of MKP5 function in metabolism, a HFD was 
given to WT mice to induce hepatic steatosis and the response of WT mice to 
HFD feeding were exmained. Upon HFD feeding, mice had a significant increase 




appeared to be much larger and paler compared with those given normal chow 
(Figure 4.3.2A). Oil red O staining revealed that there was increased 
accumulation of lipid contents in the livers of HFD feeding mice (Figure 4.3.2C). 
Consistently, significantly increased hepatic TG level was detected in the mice 
receiving HFD feeding compared with their controls (Figure 4.3.2D). These 
evidence collectively demonstrated that HFD feeding accelerated the development 
of hepatic steatosis, indicating the HFD feeding model successfully recaptured the 
disease model. 
 
Figure 4.3.2 HFD feeding accelerates the development of hepatic steatosis. (A) 
Representative pictures of livers from mice given NC or HFD for 12 weeks. (B) 
Comparison of body weight and liver weight of WT mice with NC or HFD 
feeding for 12 weeks. (C) Representative micrographs showing Oil Red O 
staining on the liver section from mice fed with NC or HFD for 12 weeks. Scale 
bar denotes 100μm. (D) Measurement of TG level in the livers of WT mice fed 
with normal chow or HFD for 12 weeks. All values are shown as the mean ± S.E.. 




To investigate the involvement of MKP5 in regulating metabolism in 
response to HFD, mRNA level of MKP5 was examined in various metabolic 
tissues including WAT, skeletal muscle and the liver from mice fed with or 
without HFD. We found that WAT had markedly higher mRNA level of MKP5 
compared with livers and skeletal muscles (Figure 4.3.3A). HFD feeding 
significantly increased the expression of MKP5 in WAT and skeletal muscle but 
not the liver. However, protein level of MKP5 appeared to be increased in the 
liver upon HFD. These results indicate the possible involvement of MKP5 in 
regulating metabolism.   
 
Figure 4.3.3 Increased MKP5 mRNA level in the WAT and skeletal muscle 
but not in the liver of mice after HFD feeding.  WT mice were fed with normal 
chow or HF diet for 8 weeks. (A) MKP5 mRNA levels in the WAT, skeletal 
muscle and liver were examined by QRT-PCR (B) MKP5 expression in the liver 
was detected by western blots. β-actin is a loading control. All values are shown 





4.3.3 Deficiency of MKP5 promotes the development of diet-induced hepatic 
steatosis  
After establishing the HFD-induced hepatic steatosis model, we next fed both 
MKP5 KO mice and age-matched WT mice with HFD to further study the 
function of MKP5 in the liver. After HFD feeding, there was no significant 
difference in body weight between WT and MKP5 KO mice (Figure 4.3.4B). 
However, we found that MKP5 KO mice had a dramatic increase in liver weight 
compared with that from WT mice after 8 and 12 weeks of HFD feeding (Figure 
4.3.4B). It was found that the increase in liver weight is probably attributed to 
increased lipid accumulation in hepatocytes since increased accumulation of lipid 
including FFA, cholesterol and TGs was detected in MKP5 KO livers compared 
with WT mice (Table 4.3.1). In line with increased liver weight, we found that 
MKP5 KO mice had larger and paler livers compared with WT mice upon 8 
weeks HFD feeding (Figure 4.3.4A). After 12 weeks HFD feeding, WT and 
MKP5 KO mice displayed more pale livers than those from mice given HFD for 8 
weeks. As expected, MKP5 KO mice had paler livers than WT mice at this stage  
To further characterize these liver samples, histological examination 
including H&E staining and Oil-red O staining was performed on the liver 
sections from WT and MKP5 KO mice fed with HFD. As shown in figure 4.3.4C, 
after 8 weeks of HFD feeding, liver section from MKP5 deficient mice displayed 
obvious vacuoles while WT liver sections did not. After 12 and 16 weeks of HFD 
feeding, there were obvious vacuoles on both WT and KO liver sections. 




those from WT mice (Figure 4.3.4C).  Interestingly, the vacuoles found in liver 
section from MKP5 KO mice were unilocular, suggesting larger lipid droplet 
formation after 16 weeks of HFD feeding. Oil-red O staining of sections from WT 
and MKP5 deficient livers further confirmed that MKP5 KO hepatocytes 
contained more and larger lipid droplets than WT cells (Figure4.3.4D). These 
evidence collectively indicated that the MKP5 KO mice were more susceptible to 





Figure 4.3.4 MKP5 KO mice are more susceptible to develop hepatic 
steatosis upon HFD feeding. (A) Representative pictures of livers from WT and 
MKP5 KO mice after 8 and 12 weeks of HFD feeding. (B) Comparison of body 




Representative micrographs showing H&E staining on the liver sections (5um) of 
WT and MKP5 KO mice fed with HFD for 8, 12 and 16 weeks. (D) 
Representative micrographs showing Oil Red O staining on liver sections (8um)  
from WT or KO mice with 12 weeks of HFD feeding. The scale bar denotes 
100µm. All values are shown as the mean ± S.E.. The statistical significance is 
relative to the WT group, *p<0.05. 
 
4.3.4 Effect of MKP5 deficiency on lipid metabolism 
Hepatic steatosis is characterized by increased TG accumulation in the 
cytoplasm of hepatocytes. To understand whether MKP5 deficiency affects lipid 
metabolism, we examined Non-esterified fatty acid (NEFA, also known as FFA), 
TG and cholesterol in both serum and livers from WT and MKP5 KO mice after 
HFD feeding. As shown in table 4.3.1, WT and MKP5 KO mice had similar 
levels of NEFA and TG in the blood after 8, 12 and 16 weeks of HFD feeding. 
Significantly increased level of serum total cholesterol was detected in the MKP5 
KO mice compared with WT controls with HFD feeding. In addition, total lipid 
was extracted from livers of WT and MKP5 KO mice after 8, 12 and 16 weeks of 
HFD feeding. There were significantly increased levels of hepatic TG, hepatic 
total cholesterol and hepatic NEFA in MKP5 KO mice compared with their WT 
control upon HFD feeding for 8, 12 and 16 weeks (Table 4.3.1). Thus, loss of 
MKP5 affects the hepatic lipid metabolism which might contribute to the 






Table 4.3.1 Measurement of lipid contents in serum and livers of WT and 
MKP5 KO mice upon HFD feeding 
 
All values are shown as the mean ± S.E.. The statistical significance is relative to 
the WT group, *p<0.05. 
4.3.5 Deficiency of MKP5 leads to increased p38 MAPK activation in the 
liver 
MKPs are major negative regulators of MAP Kinases. They dephosphorylate 
MAPKs at both phosphothreonine and phosphotyrosine residues simultaneously 
located in the activation loop of MAPKs (Zhang and Dong, 2007a). To examine 
the substrate(s) of MKP5 in the liver, the activation level of the tree main MAPKs 
in livers from WT and MKP5 KO mice was examined by western blots. As shown 
in figure 4.3.5, there was increased level of p38 phosphorylation in the livers of 
MKP5 KO mice compared with that in livers of WT mice after HFD feeding 





activation was significant. However, the activation of JNK1/2 and ERK1/2 was 
comparable in the livers of WT and MKP5 KO mice after HFD feeding. These 
results indicate that p38 MAPK is the main target of MKP5 in the liver.       
 
Figure 4.3.5 MKP5 negatively regulates p38 MAPK in the liver. 
Representative western blots showing MAPK activities in the livers of WT and 
MKP5 KO mice given HFD. Quantification of the western blots was done using 
software Image J. All values are shown as the mean ± S.E.. The statistical 




4.3.6 Comparable expression of genes involved in lipogenesis, lipolysis and 
fatty acid oxidation in the livers of  WT and MKP5 KO mice  
Hepatic steatosis is caused by imbalance of input and output of FFA and TG 
in the liver (Cohen et al., 2011). The source of FFA comes from diet, lipogenesis 
in the liver and lipolysis in adipose tissue. In the liver, TG can be hydrolyzed to 
FFA and transported into mitochondria for fatty acid oxidation (Cohen et al., 
2011). To understand the mechanism by which MKP5 deficiency led to increased 
TG accumulation, we examined the expression of various genes involved in 
lipogensis, lipolysis and fatty acid oxidation pathways. As shown in figure 4.3.6A, 
there is no significant difference in the expression of lipogenic genes including 
ACC1 and FAS as well as their regulators, SREBP1c and ChREBP. In addition, 
there is no significant difference in the expression of DGAT1 that esterifies FFA 
to form TG. Thus, deficiency of MKP5 did not affect lipogenesis pathways in the 
liver. 
Lipolysis is a biochemical pathway responsible for the catabolism of TGs 
stored in cellular lipid droplets (Lass et al., 2011). In adipocytes, insulin resistance 
increases the activity of hormone-sensitive lipase (HSL), resulting in elevated 
rates of TG lipolysis and enhanced FFA flux to the liver (Browning and Horton, 
2004). We previously observed that MKP5 KO mice developed insulin resistance 
and had increased blood fasting insulin level compared with WT controls 
(manuscript submitted). Thus, we examined the expression of lipolysis genes in 
WAT of WT and MKP5 KO mice. As shown in figure 4.3.6B, there was no 




ATGL. This was consistent with the observation that there was comparable serum 
level of FFA in WT and MKP5 KO mice (Table 4.3.1).  
Fatty acid oxidation occurs in mitochondria and plays an important role in 
hepatic energy homeostasis. We next examined the expression of genes involved 
in fatty acid oxidation and found that there was comparable expression of fatty 
acid oxidation related genes in the livers of WT and MKP5 KO mice after HFD 
feeding (Figure 4.3.6C). Thus, deficiency of MKP5 did not affect fatty acid 





Figure 4.3.6 Deficiency of MKP5 does not affect the expression of genes 
invoved in lipogenesis, lipolysis and fatty acid oxidation. (A) Expression of 
lipogenic genes was examined in the livers of WT and MKP5 KO mice by QRT-
PCR. (B) Expression of lipolysis genes was examined in the WAT of WT and 




the livers of WT and MKP5 KO mice. All values are shown as the mean ± S.E.. 
The statistical significance is relative to the WT group, *p<0.05. 
 
4.3.7 MKP5 inhibits Cidea and Fsp27/Cidec expression in the liver 
4.3.7.1 Deficiency of MKP5 leads to increased expression of Cidea and 
Fsp27/Cidec in the liver 
To further understand role of MKP5 in the development of hepatic steatosis, 
we performed microarray analysis using RNA from livers of both HFD-fed WT 
and MKP5 KO mice. According to the microarray data, Cidea and Fsp27/Cidec 
were two of the most highly induced genes in the steatotic livers from MKP5 KO 
mice. As CIDE proteins have been revealed to play important roles in regulating 
the development of hepatic steatosis in both humans and mouse (Li et al., 2007; 
Matsusue et al., 2008; Zhou et al., 2003), we were interested in examining the 
cide genes in WT and MKP5 KO mice. First, to verify the microarray data, QRT-
PCR was performed using RNA extracted from WT and KO livers. We found that 
mRNA levels of Cidea and Fsp27 were highly increased in the liver of MKP5 KO 
mice compared with those from WT mice (Figure 4.3.7A). No change in mRNA 
level of Cideb was detected. Western blot analysis showed consistent results with 
QRT-PCR, that was, there was increased protein expression of Cidea and Fsp27, 
but not Cideb, in the liver of MKP5 KO mice (Figure 4.3.7B). These evidence 






Figure 4.3.7 Deficiency of MKP5 leads to increased expression of Cidea and 
Cidec/Fsp27 in the livers. (A) mRNA levels of Cidea, Cideb and Fsp27/Cidec in 
livers of WT and MKP5 KO mice upon HFD feeding was determined by QRT-
PCR. (B) Protein levels of Cidea, Cideb and Fsp27/Cidec in livers of WT and 
MKP5 KO mice was examined by western blots. α-tublin was used as the loading 
controls. All values are shown as the mean ± S.E.. The statistical significance is 
relative to the WT group, **p<0.01.  
 
4.3.7.2 Overexpression of MKP5 inhibits Cidea and Fsp27/Cidec promoter 
activity 
The results so far have demonstrated that MKP5 KO mice had increased  




of cide genes by MKP5.  To further investigate the regulation of Cidea and 
Fsp27/Cidec by MKP5, the promoter regions of Cidea and Fsp27/Cidec were 
cloned into pGL3-basic vector and co-transfected these constructs separately with 
MKP5 cDNA (pCDNA-MKP5) or MKP5 phosphatase-inactivated mutant 
(pcDNA-MKP5 PM) into FL83B hepatocytes. Luciferase activities were 
determined with and without palmitate stimulation. We found that overexpression 
of MKP5 inhibited Cidea and Fsp27/Cidec promoter activity whereas 
overexpression of phosphatase-inactivated MKP5 did not (Figure 4.3.8). These 
results suggested that the expression of Cidea and Fsp27/Cidec was negatively 
regulated by MKP5, which was dependent on MKP5 phosphatase activity.  
 
Figure 4.3.8 Overexpression of MKP5 inhibits Cidea and Fsp27/Cidec 
promoter activity. Cidea and Fsp27/Cidec promoter regions were cloned into 
pGL3 vectors and was separately co-transfected with MKP5 cDNA or MKP5 
phosphatase inactivated mutant into FL83B hepatocytes. Luciferase activities 
were determined with or without palmitic acid stimulation. All values are shown 
as the mean ± S.E.. The statistical significance is relative to the pcDNA 





4.3.8 MKP5 regulates Cide genes through p38 MAPK 
In our study, we observed increased p38 activation together with increased 
Cidea and Fsp27/Cidec expression in the liver of MKP5 KO mice (Figure 4.3.5 
and 4.3.7), indicating a possible regulation of Cide gene expression by MKP5 
through p38 MAPK. To test this hypothesis, we did p38 MAPK inhibition on both 
hepatocytes and mice by using inhibitor SB203580 (4-(4-fluorophenyl)-2-(4-
methylsulfinylphenyl)-5-(4-pyridyl)-imidazole) and examined Cide gene 
expression with or without inhibition.  
4.3.8.1 p38 inhibition decreases the expression of Cide gene in hepatocytes  
Mouse hepatocytes FL83B cells were pretreated with p38 inhibitor 
SB203580 followed by palmitic acid stimulation for 12h and the expression of 
Cide genes was examined by QRT-PCR. As shown in figure 4.3.9, in response to 
palmitic acid, expression of Cidea and Fsp27/Cidec was upregulated significantly 
in mouse hepatocyte while Cideb mRNA level was downregulated. This suggests 
that different mechanisms present to regulate the expression of Cide genes. 
Importantly, we found that the administration of p38 inhibitor decreased the 
expression of all three Cide genes with and without palmitic acid stimulation. 
These results demonstrated that p38 MAPK was involved in the regulation of 





Figure 4.3.9 Effect of p38 inhibition on Cide gene expression. Mouse 
hepatocytes were pretreated with p38 inhibitor SB203580 for 1h followed by 
palmitic acid stimulation for 12h. Cide gene expression was detected by QRT-
PCR. All values are shown as the mean ± S.E.. The statistical significance is 
relative to the vehicle group, *p<0.05. 
 
4.3.8.2 p38 inhibition in mice decreases of Cide gene expression in the liver 
As shown above, inhibition of p38 MAPK in hepatocytes reduced the 
expression of Cidea, Cideb and Fsp27/Cidec with and without palmitic acid 
stimulation. To further understand the regulation of these genes by p38 in the liver 
during the development of hepatic steatosis, we treated mice with p38 inhibitor 
and examined the expression of Cide genes. In line with the development of more 
severe hepatic steatosis in MKP5 KO mice compared with WT mice, there is a 
significantly increased mRNA expression of Cidea and Fsp27/Cidec in the livers 
of MKP5 KO mice (Figure 4.3.10A). However, mRNA expression of Cideb in the 




decreased mRNA level of both Cidea and Fsp27/Cidec but not Cideb in the livers 
of both WT and MKP5 KO mice (Figure 4.3.10A). Western blot analysis 
demonstrated that p38 inhibition decreased the protein expression of Fsp27/Cidec 
but not Cideb in the liver of both WT and MKP5 KO mice (Figure 4.3.10B). The 
good quality of anti-Cidea antibody was not commercially available. However, 
weak detection of Cidea was still possible with the existing antibody as shown in 
figure 4.3.10B. There was a slight decrease in Cidea protein in the liver of both 
WT and MKP5 KO mice upon p38 inhibitor treatment. These evidence indicated 
that (1) p38 MAPK regulates the expression of Cidea and Fsp27/Cidec in the 
development of hepatic steatosis; (2) the regulation of expression of Cidea and 





Figure 4.3.10 p38 inhibition results in decreased expression of Cidea and Fsp27/cidec in the livers from both WT and MKP5 
KO mice. (A) mRNA levels and (B) protein levels of Cide genes in the livers of WT and MKP5 KO mice treated with p38 inhibitor 




4.3.8.3 p38 inhibition attenuates the development of hepatic steatosis in WT 
and MKP5 KO mice 
The development of hepatic steatosis in MKP5 KO mice was associated with 
increased p38 MAPK activation and increased Cidea and Fsp27/Cidec expression 
in the liver (Figure 4.3.5 and 4.3.7), which raised a possibility that inhibition of 
p38 MAPK activity may help reduce the disease in MKP5 KO mice by 
downregulating Cidea and Fsp27/Cidec in the liver. To address this, mice given 
HFD were administrated with p38 MAPK inhibitor daily by oral gavage feeding. 
As shown in figure 4.3.11A, MKP5 KO mice gained more weight than WT mice 
upon HFD feeding.  p38 inhibition significantly reduced the body weight gain in 
both WT and MKP5 KO mice. Reduced liver weights were observed in both WT 
and MKP5 KO mice treated with inhibitor compared with those from the control 
mice, although the decrease did not reach statistical significance. Histological 
examination of the liver sections showed that MKP5 KO mice developed more 
severe hepatic steatosis than WT mice upon HFD feeding (Figure 4.3.4D). After 
treatment with p38 inhibitor, both WT and MKP5 KO mice had improved hepatic 
steatosis. However, MKP5 KO mice still displayed more severe steatosis than WT 
mice (Figure 4.3.11D). Quantification of lipid contents in the liver revealed that 
MKP5 KO mice had more hepatic TG than WT mice. The treatment with p38 
inhibitor lowered the hepatic TG levels in both WT and MKP5 KO mice (Figure 
4.3.11C). Thus, p38 MAPK is involved in regulation of the development of 
hepatic steatosis. Furthermore, the function of MKP5 in regulating the 
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development of hepatic steatosis is possibly in part achieved through regulation of 




Figure 4.3.11 p38 inhibition attenuates the development of hepatic steatosis 
in both WT and MKP5 KO mice upon HFD feeding. (A) Body weight gain of 
WT and MKP5 KO mice after treatment with p38 inhibitor SB203580 or vehicle. 
(B) Body weight and liver weight as well as (C) hepatic TG level and hepatic 
NEFA level of mice with or without p38 inhibitor treatment were determined. (D) 
Representative micrographs showing H&E on liver sections  of WT and MKP5 
KO mice treated with or without p38 inhibitor. Scale bar denotes 100μm. Data are 
shown as mean ± S.E.. The statistical significance is relative to the vehicle treated 
groups, *p<0.05. 
4.3.9 Generation and characterization of hepatocytes constitutively 
expressing MKP5  
To further understand the regulation of MKP5 in the liver, we transfected 
FL83B mouse hepatocytes with MKP5 full-length cDNA construct or empty 
vector. Subsequently, selection was conducted with drug puromycin to generate 
hepatocyte cell clones constitutively expressing MKP5. QRT-PCR results 
revealed that among clones obtained, clone 1, 3 and 8 had around 2~4 folds more 
MKP5 expression than control cells (Figure 4.3.12A). Western blots showed that 
these clones had obviously increased MKP5 protein expression compared with the 
control cells (Figure 4.3.12A).  Next, we examined MAPK activation in these 
cells in response to palmitic acid (PA) stimulation. Upon PA stimulation, the 
activation p38 MAPK, ERK and JNK was significantly increased.  
Overexpression of MKP5 inhibited the activation of p38 MAPK, ERK and JNK 
activation with or without PA stimulation (Figure 4.3.12B). These suggests (1) 
MAPK signaling pathway is involved in response to PA (2) MKP5 can negatively 
regulate p38MAPK, ERK and JNK in hepatocytes. (3) The overexpression of 
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MKP5 in hepatocytes is successful and these cells can be used for further 
experiment. 
 
Figure 4.3.12 Generation of MKP5 overexpressed hepatocyte cell lines. (A) 
mRNA and protein expression of MKP5 was detected in different cell clones (B) 
MAPK activation in stably MKP5 overexpressing cell line in response to PA 
stimulation. Data were presented as mean ± S.E.  
 
4.3.10 Identification of AP-1 binding sites in the promoter region of Cide 
genes 
To further understand the regulation of Cide gene expression by p38 MAPK 
and MKP5, we next identified AP1 binding sites in the promoters of CIDE genes 
by performing Chromatin Immunoprecipitation (ChIP) experiment using antibody 
against p-ATF2, which was is normally activated in response to signals that 
converge on p38 MAPK (Breitwieser et al., 2007). In line with the luciferase 
result, PA stimulation increased  p-ATF2 binding to the promoter regions of 
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Cidea, Cideb and Fsp27/Cidec.  Overexpression of MKP5 inhibited the binding 
with or without PA stimulation compared with controls (Figure 4.3.13). This 
suggests that MKP5 regulates p-ATF2 binding at the promoter regions of Cide 
family genes to control their transcription. 
 
Figure 4.3.13 Overexpression of MKP5 attenuates the p-ATF2 binding to the 
promoter of Cidea, Cideb and Fsp27/Cidec . Mouse hepatocytes with or without 
MKP5 overexpression were harvested after treatment with BSA or palmitic acid 
for 9h for ChIP assay. ChIP assay was performed using p-ATF2 antibody to 
detect AP-1 binding sites in Cide promoters. The enriched DNA was finally 
quantified by QRT-PCR. Data are presented as mean ± S.E.. The statistical 





In addition to the important role of MKP5 in the development of obesity and 
insulin resistance (manuscript submitted), we demonstrated that MKP5 played a 
protective role in the development of hepatic steatosis. Mice deficient in MKP5 
had an increased accumulation of TGs in the liver and developed hepatic steatosis 
under normal chow at a later stage of life (Figure 4.3.1). Upon HFD feeding, 
MKP5 KO mice developed more severe hepatic steatosis compared with WT 
mice, which was associated with increased p38 MAPK activity in the liver 
(Figure 4.3.4 and 4.3.5). Interestingly, deficiency of MKP5 led to dramatically 
increased expression of lipid-droplet-associated protein genes including Cidea 
and Fsp27/Cidec in the liver (Figure 4.3.7). Furthermore, overexpression of 
MKP5 inhibited Cidea and Fsp27/Cidec promoter activity in hepatocytes, which 
was dependent on the phosphatase activity of MKP5 (Figure4.3.8). We further 
found that treatment of p38 MAPK inhibitor, SB203580, alleviated hepatic 
steatosis in WT and MKP5 deficient mice by reducing expression of Cidea and 
Fsp27/Cidec in the liver (Figure 4.3.10 and 4.3.11). In addition, overexpression of 
MKP5 inhibited the p-ATF2 binding to the AP1 binding sites in the promoter 
regions of Cide genes, indicating AP-1 binding sites were identified in the 
promoter regions of Cidea and Fsp27/Cidec (Figure 4.3.13). Therefore, MKP5 
plays an important protective role in the development of hepatic steatosis by 
regulating Cidea and Fsp27/Cidec possibly through p38 MAPK in the liver. 
Besides MKP5, MKP1 and MKP3 were also implicated in metabolic diseases, 
indicating that MKP protein family plays important roles in the regulation of 
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energy homeostasis (Feng et al., 2014; Flach et al., 2011; Wu et al., 2006; Xu et 
al., 2005a).  Interestingly, different MKPs have been shown to have distinct roles 
in metabolism. For instance, deficiency of MKP1 or MKP3 protects mice from 
diet-induced obesity and obesity-related metabolic disorders including hepatic 
steatosis, while MKP4 and MKP5 KO mice are more susceptible to develop 
hepatic steaosis (Flach et al., 2011; Wu et al., 2006; Xu et al., 2003b; Xu et al., 
2005a). The different roles of these MKPs in metabolism could be due to their 
different regulation on the activation of MAPKs. MKP1 can dephosphorylate p38, 
ERK and JNK in metabolic tissues such as muscles (Wu et al., 2006). However, 
MKP3 has been shown mainly to target ERK (Xu et al., 2005a). In our findings, 
MKP5 is preferentially inactivate p38 MAPK in the liver. Thus, the different 
substrate(s) of MKPs may contribute to their distinct effect on metabolism. 
Although MAPKs are believed to be the major substrates of MKPs, other proteins 
including FOXO1 and PPAR have been demonstrated to be the targets of MKPs 
(Wu et al., 2006; Xu et al., 2005a). For instance, it has been reported that MKP1 
can directly dephosphorylate PPARα (Wu et al., 2006). Recently, our group found 
that MKP5 can dephosphorylates IRF3 in BMDMs (manuscript submitted). Such 
substrate differences between different MKPs possibly contribute to the different 
metabolic phenotypes observed in different MKP KO mice.  
Previously, we found that MKP5 KO male mice had significantly increased 
body weight at the age of 5 months as compared with their WT control. At this 
age, MKP5 KO mice also had larger perigonadal fat pads and increased adipocyte 
sizes, indicating that MKP5 KO mice developed obesity (manuscript submitted). 
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Interestingly, when the mice were at the age of 8 months, they had decreased size 
and weight of perigonadal fat pads with increased size and weight of the liver. 
However, no significant difference on body weight was detected between WT and 
MKP5 KO mice upon HFD feeding. The negative correlation between the size 
and weight of adipose tissue and liver in MKP5 KO mice led us to hypothesize 
that a possible mechanism regulating lipid re-distribution from adipose tissues to 
livers exist in MKP5 KO mice. To study the hypothesis, fluorescence- labelled 
lipids can be injected into adipose tissue of WT and MKP5 KO mice after 8 or 12 
weeks HFD feeding. After 24 hours, livers were isolated to measure density of 
fluorescence to determine the re-distributed lipid contents in WT and MKP5 KO 
mice. Therefore, the regulation of lipid redistribution from adipose tissue to livers 
by MKP5 can be eludiated. 
Previously, it has been shown that MKP5 targeted both JNK and p38 when 
MKP5 was overexpressed in NIH 3T3 cells (Tanoue et al., 1999; Theodosiou et 
al., 1999) and it negatively regulated JNK in immune cells (Zhang et al, 2004). 
JNK MAPK has been reported to play important roles in inflammation, obesity 
and obesity-related insulin resistance (Bastard et al., 2006; Hirosumi et al., 2002). 
In our study, we interestingly detected increased activation of p38 MAPK but not 
JNK or ERK in the livers from MKP5 KO mice as compared with those from WT 
mice (Figure 4.3.5). These information suggests the regulation of MAP kinase 
activation by MKP5 exhibits a tissue specific manner. In fact, such cell or tissue 
specific regulation of MAPK activation is not specific to MKP5. For instance, 
MKP1 dephosphorylates p38, JNK and ERK in the adipose tissue. However, 
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MKP1 inhibits the activation of JNK and p38 but not ERK in the liver (Wu et al., 
2006). Several regulatory mechanisms could explain such cell type or tissue 
specific regulation of MAPK activation by MKPs. First, MKP family consists of 
about 11 members. Loss of one MKP may results in the compensation effect of 
other MKPs on regulating MAPK activation in specific cells or tissues. In our 
study, we found that loss of MKP5 upregulated some MKPs such as Dusp3 and 
also downregulated some MKPs like MKP7. In addition, comparable expression 
of MKPs such as MKP2 and Dusp8 was detected in WT and MKP5 KO liver. 
Second, scaffold proteins may assemble MAPK signaling complex to restrict the 
accessibility of one MKP to its substrate(s) in a cell or tissue specific manner. 
Third, our observation of increased p38 MAPK activation in livers of MKP5 KO 
mice may be due to increased cell stress or inflammation or both since we 
detected increased lipid accumulation and increased inflammatory gene 
expression in the livers of MKP5 KO mice as compared with those of WT mice. 
Our microarray analysis of WT and MKP5 KO liver samples led to the 
identification of the CIDE family genes as potential targets of MKP5. Previously, 
CIDE family genes have been reported as important mediators for lipid 
metabolism and regulate the development of hepatic steatosis (Li et al., 2007; 
Matsusue et al., 2008; Zhou et al., 2003). Since we have used liver tissue for the 
mRNA analysis, there is a possibility that the increased expression of Cide genes 
may be a consequence of increased lipid accumulation, rather than a direct effect 
of MKP5 deficiency. To address this question, we overexpressed MKP5 in liver 
cells and detected a decreased CIDE genes expression without any changes in 
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lipid accumulation. In addition, we identified AP1 binding sites in the promoter 
region of CIDE genes. Using luciferace assay, we also proved that these sites 
were needed for maximal promoter activity and MKP5 had suppressive effect on 
the activity.  
The development of hepatic steatosis in MKP5 KO mice was shown to be 
associated with increased p38 MAPK activation and increased Cidea and 
Fsp27/Cidec expression in the liver, which raised the possibility that inhibition of 
p38 MAPK activity may improve the disease condition in MKP5 KO mice. To 
address this, p38 MAPK inhibition experiments were performed by oral 
administration of p38 inhibitor. Although p38 inhibitor treatment significantly 
reduced the expression of Cidea and Fsp27/Cidec in the livers of both WT and 
MKP5 KO mice, the inhibition only attenuated the development of hepatic 
steatosis in both WT and MKP5 KO mice moderately. This suggests that p38 
partially inhibits the development of hepatic steatosis and other mechanism (s) 
present that contribute to the development of hepatic steatosis in MKP5 KO mice. 
Besides, p38 inhibitor was orally administrated on WT and MKP5 KO mice in 
this study. The effect of p38 inhibition may be not merely on livers of WT and 
MKP5 KO mice. Thus it is difficult to tell whether this effect is directly mediated 
in liver or it could be an indirect effect through affecting energy dissipation. To 
address this, the mice with or without p38 inhibitor treatment could be monitored 
in the metabolic cages to determine the energy intake and energy expenditure. In 
addition, MKP5 x p38 liver-specific knockout mice could also be beneficial to 
clearly address this question in the future. 
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In our HFD model, we observed significant difference in liver weight 
between WT and MKP5 KO mice, while the body weight was similar. However, 
MKP5 mRNA expression was significantly induced by HFD in the adipose tissue, 
but not in the liver. The failure to detect changes of MKP5 expression in the liver 
upon HFD could be due to the timing where the gene expression was examined. It 
is also possible that the development of hepatic steatosis in MKP5 KO mice might 
be a second effect of adipose tissue dysfunction in obesity.  HFD feeding led to 
increased fat accumulation in WAT of WT mice, which induced MKP5 
expression to help WAT to deal this change. However, in MKP5 KO animals, due 
to lack of MKP5, adipose tissue has limited ability to store extra lipids.  As a 
consequence, liver became the alternative site for lipid storage and the increased 
expression of Cide proteins due to lack of MKP5 in the liver further facilitated the 
accumulation of lipids. As a consequence, hepatic steatosis developed. To clearly 
understand the mechanism, liver specific or WAT specific MKP5 KO mice could 
be utilized to investigate if the development of hepatic steatosis in MKP5 KO 
mice was due to MKP5 deficiency either in liver or WAT or in both. In addition, 
mice with adenovirus-mediated overexpression of MKP5 in the liver could also 
be beneficial to study the function of MKP5 in the development of hepatic 
steatosis.  
4.5 Conclusion 
In this study, we have systemically investigated the role of MKP5 in 
regulating development of hepatic steatosis. This study mainly consisted of three 
parts: (i) understanding the roles of MKP5 in development of hepatic steatosis; (ii) 
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Examination on substrate(s) of MKP5 in the liver; (iii) investigation on the 
mechanism by which MKP5 regulates the development of hepatic steatosis. The 
main findings are: 
       (1) MKP5 protects mice from development of hepatic steatosis 
           (i) MKP5 KO mice develop hepatic steatosis at later stage of life after 
normal chow diet feeding 
           (ii) MKP5 KO mice are more susceptible to HFD-induced hepatic steatosis 
       (2) MKP5 preferentially targets p38 MAPK in the liver 
       (3) MKP5 regulates the development of hepatic steatosis by targeting Cidea 
and Fsp27/Cidec, which is mediated by p38 MAPK.  
           (i) Deficiency of MKP5 results in dramatically increased expression of 
Cidea and Fsp27/Cidec in the liver. Overexpression of MKP5 inhibits Cidea and 
Fsp27/Cidec promoter activity, which depends on MKP5 phosphatase activity. 
           (ii) p38 MAPK inhibition leads to decreased expression of Cidea and 
Fsp27/Cidec and attenuates hepatic steatosis in both WT and MKP5 KO mice 
           (iii) AP-1 binding sites were identified in the promoter region of Cidea and 
Fsp27/Cidec 
 Taken together, we have demonstrated the crucial role of MKP5 in 
regulating hepatic steatosis development. We believe that data from this study 
will contribute to current literature for the function of MKP5, particular in control 
of hepatic steatosis, which provide a foundation for the development of novel 
therapeutic strategies for non-alcoholic fatty liver diseases such as hepatic 
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